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The chromatin-associated protein WDR5 is a promising target for pharmacological inhibition in 
cancer. Drug discovery efforts center on the blockade of the “WIN site” of WDR5, a well-defined 
pocket that is amenable to small molecule inhibition. Various cancer contexts have been proposed 
to be targets for WIN site inhibitors, but a lack of understanding of WDR5 target genes and of the 
primary effects of WIN site inhibitors hampers their utility. Here, by the discovery of potent WIN 
site inhibitors, we demonstrate that the WIN site links WDR5 to chromatin at a small cohort of 
loci, including a specific subset of ribosome protein genes. WIN site inhibitors rapidly displace 
WDR5 from chromatin and decrease the expression of associated genes, causing translational 
inhibition, nucleolar stress, and p53 induction. Our studies define a mode by which WDR5 
engages chromatin and forecast that WIN site blockade could have utility against multiple cancer 
types.
Graphical Abstract
In Brief
WDR5 is a chromatin-associated protein and promising anti-cancer target. Aho et al. show that 
WDR5 controls the expression of ribosome protein genes and describe how small molecule 
inhibitors of WDR5 displace it from chromatin, causing impeded translation, nucleolar stress, and 
induction of p53-dependent apoptosis in leukemia cells.
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INTRODUCTION
Increased awareness of the importance of epigenetic processes in cancer has fueled interest 
in the concept that epigenetic regulators can be targeted to treat malignancy. A collection of 
epigenetic regulators has been subject to small molecule inhibition in recent years, including 
histone methyltransferases, his-tone deacetylases, and proteins that bind modified histones. 
There are dozens of small molecule epigenetic inhibitors in clinical trials in the United 
States (Bennett and Licht, 2018), but as the likelihood of approval of investigational 
oncology drugs is small, drugs against additional targets are needed to increase the chances 
that one of these agents will improve our ability to treat cancer.
One epigenetic regulator that has received considerable attention as a cancer target is 
WDR5. WDR5 is a WD40-repeat protein that scaffolds the assembly of multiple epigenetic 
“writers,” including the non-specific lethal (NSL) and Ada2-containing (ATAC) histone 
acetyltransferase (HAT) complexes and the MLL/SET-type histone methyltransferases 
(HMTs) that catalyze histone H3 lysine 4 (H3K4) di- and tri-methylation (Guarnaccia and 
Tansey, 2018). Aberrant WDR5 expression is implicated in a variety of cancers, such as 
leukemias (Ge et al., 2016), breast cancer (Dai et al., 2015), and bladder cancer (Chen et al., 
2015). In addition, WDR5 has been shown to play a critical role in promoting the epithelial-
to-mesenchymal transition (Wu et al., 2011), it serves as a co-factor for MYC (Carugo et al., 
2016; Thomas et al., 2015), and it is a promising therapeutic target in a number of 
bloodborne and solid cancers (Cao et al., 2014; Grebien et al., 2015; Zhu et al., 2015). 
Highly potent drug-like inhibitors of WDR5—if they can be discovered—could have a 
tremendous impact in the clinic.
From a structural perspective, the most obvious route to pharmacologically inhibit WDR5 is 
via the WIN (WDR5 interaction) site, a well-defined pocket that mediates interaction with 
an arginine-containing motif (WIN motif; consensus “ARA”) present in multiple WDR5-
interaction partners (Guarnaccia and Tansey, 2018). Although the functions of the WIN site 
are not fully understood, it is clear that the HMT activity of complexes carrying the MLL1 
protein, but not other mixed lineage leukemia/Su(var)3–9, Ezh2, Trithorax (MLL/SET) 
family members, is dependent on WIN site binding by a WIN motif (Alicea-Velázquez et al., 
2016), leading to the concept that WIN site inhibitors could alter transcriptional patterns by 
modulating H3K4 methylation. Consistent with this idea, a moderately potent (Kd ~100 nM) 
small molecule WIN site inhibitor inhibits cancer cells that express mutant forms of 
CCAAT-enhancer-binding protein α (C/EBPα) (Grebien et al., 2015) and p53 (Zhu et al., 
2015). Additionally, higher affinity (Kd ~1 nM) peptidomimetics against the WIN site 
temper H3K4 methylation and inhibit leukemia cells bearing rearrangements in the MLL1 
gene (Cao et al., 2014). Whether WIN site inhibitors work by directly affecting H3K4 
methylation or whether these changes are a secondary consequence of some other 
perturbation of the WIN site, however, is unknown. Compounding this issue is the relative 
lack of understanding of the types of genes controlled by WDR5, making it difficult to 
predict the primary transcriptional consequences of WIN site blockade.
Given the therapeutic potential of targeting WDR5 in cancer, we sought to independently 
discover small molecule inhibitors of the WIN site and to characterize their primary 
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mechanism of action in the well-studied context of MLL1-rearranged (MLLr) cancer cells. 
Here, we used fragment-based approaches, coupled with structure-based design, to identify 
inhibitors that bind tightly to the WIN site of WDR5—in our best case, with an affinity in 
the picomolar range. We show that these inhibitors result in the rapid and comprehensive 
displacement of WDR5 from chromatin and lead to a commensurate decrease in the 
expression of WDR5-bound genes. We also define how these compounds inhibit 
proliferation and induce apoptosis in MLLr cancer cells. These studies reveal a primary 
mechanism of action of WIN site inhibitors, illuminate gene regulatory networks driven by 
WDR5, and forecast that drug-like WIN site inhibitors could have broad anti-cancer activity.
RESULTS
Discovery of WIN Site Inhibitors
To identify small molecules that bind the WIN site, we conducted a fragment-based screen 
of ~13,800 compounds by acquiring SOFAST 1H-15N heteronuclear multiple quantum 
coherence (HMQC) spectra of WDR5 (Wang et al., 2018). An initial HMQC spectrum of 
uniformly 15N-labeled WDR5 with an unlabeled MLL1 WIN peptide highlighted peak shifts 
that correspond to amino acids in the vicinity of the WIN site. Mixtures of 12 fragments 
were incubated with labeled WDR5 protein, and those that caused peak shifts similar to the 
MLL1 peptide were flagged as WIN site hits. Follow-up screening of individual compounds 
from the hit mixtures identified 47 hits. One of these fragment hits is compound C1 (Figure 
1A), which binds WDR5 with a Kd of ~66 μM (Table S1). We solved the X-ray crystal 
structure of C1 when complexed with WDR5 (Figure 1B; Table S2) and found that the 
cyclic guanidine of C1 binds deep into the S2 pocket of WDR5 (Wang et al., 2018), 
mimicking the arginine of the WIN peptide. To improve the affinity of C1, we used 
structure-based design to access nearby pockets. Growing out to S7 with a benzyl amide 
yielded compound C2 (Figure 1A), with a ~3,000-fold improvement in affinity. In the X-ray 
structure of WDR5 bound to C2 (Figure 1C; Table S2), the benzyl group occupies the S7 
pocket, anchored by additional hydrogen-bonding interaction of the carbonyl oxygen with 
the backbone NH of Cys-261. Further optimization of C2 led to C3 (Figure 1A), with a Kd 
of 1.3 nM. Compound C3 provides improved potency by modifying the substituents on the 
benzylic ring to better occupy the S7 pocket and by inclusion of a fluorine atom on the 
phenyl core that points toward the S4 pocket (Figure 1D; Table S2). C3 is our first-
generation chemical probe to explore the cellular consequences of WIN site blockade. To aid 
in these studies, we designed a negative control compound, C3nc (Figure S1A), that has the 
same molecular weight as C3 but binds WDR5 with reduced affinity due to the 
regioisomeric fluorine atom that clashes with the protein.
To obtain a more potent probe, we started with a different fragment hit (C4; Figure 1E). 
Although C4 bound the S2 pocket as shown in the X-ray structure (Figure 1F; Table S2), it 
did not bind to any of the nearby binding sites. Accessing the S7 pocket (Figure 1G; Table 
S2) led to compound C5, which has improved binding affinity. A further improvement in 
affinity was achieved by occupying the S4 pocket with compound C6 (Figures 1H, S1B, and 
S1C; Table S2). C6 has a Kd of ~100 pM and served as our second-generation chemical 
probe. As with C3, we obtained a negative control, C6nc, in this instance by adjusting the 
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attachment point of the S2 imidazole-imine “warhead” to yield a compound with a >1,000-
fold reduction in binding affinity (Figure S1A). For C3 and C6, we performed direct affinity 
measurements using surface plasmon resonance and found that in both cases their affinity 
for WDR5 was within 2-fold of the values calculated by time-resolved fluorescence energy 
transfer (TR-FRET) (Figure S1D). Representative data from affinity measurement 
experiments is shown in Figures S1E and S1F. As expected, C3 and C6 inhibit the HMT 
activity of MLL/SET complexes containing MLL1 and do so in a manner that reflects their 
affinity for the WIN site (Table S1). Profiling C6 against all MLL/SET complexes (Table 
S1), we found the inhibition to be specific for MLL1, with little activity against other 
MLL/SET family members. We used C3 and C6 and their negative controls to interrogate 
the biological consequences of WIN site blockade.
C3 and C6 Inhibit Leukemia Cell Lines In Vitro
The WIN site peptidomimetic MM-401 inhibits cell lines and primary transformed cells 
carrying MLL1 rearrangements (Cao et al., 2014). We asked whether C3 and C6 show 
similar activity. We profiled a collection of human leukemia lines, as well as human CD34+ 
cord blood cells transformed by the expression of an MLL-AF9 fusion protein (MA93), 
either alone or in conjunction with FMS-like tyrosine kinase-3-internal tandem duplication 
(FLT3-ITD) (MA93 FLT3-ITD) or NrasG12D (MA93 Ras) onco-genes (Wei et al., 2008). We 
also tested the murine Mll-Af9; NrasG12D cell line RN2, derived from the spleens of 
terminally ill leukemic mice (Mazurek et al., 2014). We treated cells with increasing doses 
of compounds for 3 days and measured viable cell numbers compared to DMSO-treated 
controls (Table 1). Four trends were apparent from this analysis. First, MLLr cell lines are 
generally more sensitive than non-MLLr cells to both C3 and C6. Second, the tighter WIN 
site binder C6 has higher cellular potency than C3 in all sensitive lines. Third, negative 
control compounds C3nc and C6nc have little, if any, activity in any cell type. Fourth, a 
robust response to these inhibitors appears to correlate with p53 status, as MLLr leukemia 
lines with wild-type (WT) p53 were more sensitive than lines with mutant p53.
For two representative cell lines, MV4:11 (sensitive) and K562 (insensitive), we performed 
cellular thermal shift assays (CETSAs) (Jafari et al., 2014) to track the ability of compounds 
to bind WDR5 in vivo (Figure S2). For both compounds, we observed a significant decrease 
in target engagement compared to their affinity for WDR5, with half-maximal effective 
concentration (EC50) values in cells being between 600- and 2000-fold higher than Kd 
values measured with purified WDR5 in vitro. Nonetheless, we found that the ability of C3 
and C6 to bind WDR5 in cells tracks with compound potency and that there are no major 
differences in how each compound interacts with WDR5 in each cell type. Differential 
cellular response to these compounds, therefore, is not due to differences in target 
engagement. These data demonstrate that C3 and C6 inhibit MLLr lines in vitro in a manner 
that reflects their relative affinities for WDR5, and they suggest that p53 may be involved in 
the cellular response to these inhibitors.
WIN Site Inhibition Induces p53-Dependent Cell Death
We asked how C6 inhibits MV4:11 cells in culture. A time-course analysis revealed that 
inhibition of proliferation can be detected within a few days of treatment at the 50% growth 
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inhibition (GI50) concentration (Figure 2A) and that between 2 and 6 days of treatment, 
there is a progressive decrease in cellular viability (Figure S3A). Analysis of cell-cycle 
distribution demonstrated that C6 caused a time-dependent increase in cells with a sub-G1 
DNA content (Figures 2B and S3B), which is consistent with the induction of programmed 
cell death. Probing for more sensitive and direct hallmarks of apoptosis, we found that C6 
promotes the caspase-mediated cleavage of poly (ADP-ribose) polymerase 1 (PARP-1) 
(Figure 2C), as well as the appearance of apoptotic cells, as measured by annexin V staining 
(Figure 2D). Notably, we could detect cleaved PARP-1 within 24 h following treatment, 
indicating that C6 begins to initiate apoptotic processes soon after exposure.
Because p53 status appears to correlate with sensitivity to our WIN site inhibitors (Table 1), 
we asked whether p53 is induced by C6 and whether the cellular inhibition we observe in 
response to C6 is p53 dependent. Western blotting demonstrated that a 24-h treatment of 
MV4:11 cells with C6 moderately induces p53, as well as the canonical p53 target gene p21 
(Figure 2E). To determine whether p53 status affects compound sensitivity, MV4:11 cells 
were transduced to express one of two short hairpin RNAs (shRNAs) against p53, or a 
scrambled shRNA control, and treated for 3 days with C6nc or C6. These shRNAs reduce 
steady-state p53 levels to different extents (Figure 2F), but both decrease the sensitivity to 
C6 (Figure 2G) and do so in a manner that correlates with the extent of p53 knockdown; the 
least effective shRNA against p53 (shRNA_427) increased the GI50 of C6 from ~2 μM to ~8 
μM, whereas the most potent (shRNA_941) increased the GI50 to 15 μM. To confirm these 
findings, we used CRISPR-mediated genome editing to create p53 null clones of MV4:11 
cells (Figure S3C) and found that these clones also have a reduced sensitivity to C6 (Figure 
S3D). Finally, we showed that p53 and p21 are also induced by 24-h C6 treatment in 
Molm13 cells (Figure 2H) and that CRISPR-generated p53 null Molm13 clones (Figure 2I) 
are less sensitive to C6 than clones in which p53 is intact (Figure 2J). Based on these 
findings, we conclude that WIN site inhibition induces p53 within 1 day of exposure and 
that a significant portion of the mechanism of cellular inhibition in response to C6 is p53 
dependent.
WIN Site Inhibition Represses WDR5-Bound Genes Involved in Protein Synthesis
To illuminate the mechanism through which cells respond to WIN site inhibition, we 
performed RNA-sequencing (RNA-seq), examining the effects of a 3-day treatment of 
MV4:11 cells with C6 or C6nc (Figure S4A). Consistent with its lack of biological activity, 
C6nc had no significant effect on gene expression levels in these cells (Figure 3A). 
Compound C6, in contrast, resulted in a number of significant gene expression changes, 
increasing the expression of 72 genes and decreasing the expression of 462 genes (Figure 
3A). Gene Ontology (GO) enrichment analysis failed to identify strong biological clustering 
among C6-induced genes (Figure S4B), but for repressed genes we identified two highly 
significant annotation clusters (Figure 3B). Cluster 1 is connected to protein synthesis and is 
composed of a subset of large and small ribosome protein genes (RPGs), some nuclear 
encoded mitochondrial RPGs, and translation initiation factors. Cluster 2 is connected to 
DNA replication and the cell cycle and includes cyclins and cyclin-dependent kinases, as 
well as DNA replication factors such as proliferating cell nuclear antigen (PCNA) and 
components of the mini-chromosome maintenance protein (MCM) complex. Gene set 
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enrichment analysis (GSEA) (Subramanian et al., 2005) strengthened these connections, 
with highly significant (false discovery rate [FDR] q = 0.0) enrichments in pre-ranked 
Reactome gene sets connected to translation, DNA replication, the cell cycle, and cell-cycle 
checkpoints (Figure 3C), and GO gene sets connected to the ribosome, translation initiation, 
and DNA helicase activity (Figure S4C). From this analysis, we conclude that WIN site 
inhibition decreases the expression of specific sets of genes that are connected to protein 
synthesis and the cell cycle and DNA replication.
It is reasonable to expect that the gene expression changes that we observe in response to 
WIN site inhibition are a combination of primary changes resulting from WIN site blockade 
and secondary changes that occur in response to the primary perturbations. It is also 
reasonable to expect that WDR5-bound genes will most likely be the primary targets of WIN 
site inhibitors. To focus our studies, therefore, we performed chromatin immunoprecipitation 
coupled to next-generation sequencing (chromatin immunoprecipitation sequencing [ChIP-
seq]) to determine the location of WDR5 on chromatin in MV4:11 cells. Using a 
monoclonal antibody against WDR5 (D9E1I; Cell Signaling Technology), we tracked 158 
high-confidence binding sites for WDR5 (Table S3), the majority of which were also 
detected by a different anti-WDR5 antibody (429A; Bethyl Laboratories) (Figure 3D; Table 
S3). These WDR5-binding sites are predominantly promoter proximal (Table S3), and 
among WDR5-bound genes we observed a strong biological clustering under GO terms 
connected to the ribosome (Figure 3E). Indeed, WDR5 is bound to a specific subset of 
RPGs, corresponding to genes encoding ~40% of the small and ~70% of the large ribosome 
subunit proteins. Binding of WDR5 to these genes occurs almost always within 500 bp 
downstream of the transcription start site (TSS; Figure 3F). We also observed WDR5 
binding to genes encoding a subset of translation initiation factors (Table S3). This pattern of 
binding to specific RPGs is observed across disparate cell types (Figure S4D), suggesting 
that these RPGs are a major—and conserved—class of genes bound by WDR5. Comparing 
the ChIP-seq and RNA sequencing (RNA-seq) datasets, we observed that there is a strong 
tendency for WDR5-bound genes to be repressed by C6 treatment. Only 1 WDR5-bound 
gene is induced by C6 (Figure 3G), in contrast to 59 (37%) that are repressed (Figure 3H). 
Of the 59 repressed genes, 39 encode subunits of the ribosome, supporting the concept that 
these RPGs may be direct targets of WIN site blockade. Notably, we did not observe genes 
connected to the cell cycle or DNA replication (cluster 2) in the WDR5 ChIP-seq data, 
suggesting that changes in the expression of these genes may be a secondary consequence of 
WIN site inhibition.
Finally, we asked whether OICR-9429 (Grebien et al., 2015), a chemically distinct WIN site 
inhibitor, acts similarly to C6. OICR-9429 is less potent than C6, having a 3-day GI50 in 
MV4:11 cells of 31 μM (Figure S4E), compared to 2 μM for C6 (Table 1). When MV4:11 
cells were treated with equal concentrations of OICR-9429 and C6, only C6 inhibited the 
transcription of RPGs (Figure S4F). When the concentrations were adjusted to reflect the 
relative GI50 values, however, OICR-9429 selectively inhibited the transcription of WDR5-
bound RPGs (Figure S4F) and induced both p53 and p21 (Figure S4G). Thus, despite 
differences in potencies, repression of RPG transcription and induction of p53 are common 
actions of WIN site inhibitors.
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Together, these findings expose a link between WDR5 and the ribosome protein genes and 
suggest that this class of genes may be a direct target of WIN site inhibitors. By extension, 
these findings also suggest that WIN site inhibitors may act in cells by disrupting the 
integrity of the protein synthesis machinery.
WIN Site Inhibition Promotes Translational Stress and Stimulates p53 Protein Synthesis
To determine whether WIN site blockade affects protein synthesis, we treated MV4:11 cells 
for 1–6 days with C6, pulsed with O-propargyl-puromycin (OPP) to label nascent 
polypeptide chains (Liu et al., 2012), and we quantified OPP incorporation by fluorescent 
OPP tagging and flow cytometry (Signer et al., 2014). As early as 1 day after treatment, C6 
caused a measurable reduction in OPP incorporation (Figures 4A and S5A), with mean OPP 
fluorescence decreasing and shifting toward that observed in the presence of the protein 
synthesis inhibitor cycloheximide (CHX). The impact of C6 on protein synthesis capacity 
increased across the time course of the experiment, and at 6 days, roughly half of the cells in 
the C6-treated population incorporated OPP at levels similar to those of cells treated with 
CHX. Consistent with diminished translational capacity, C6-treated MV4:11 cells also 
displayed redistribution of nucleophosmin (NPM1) from the nucleolus to the nucleoplasm 
(Figures 4B and S5B), a characteristic of nucleolar stress (Russo and Russo, 2017). Thus, 
aligned with decreased expression in protein synthesis components, C6 imposes a choke on 
the translational capacity of MV4:11 cells and triggers nucleolar stress.
We were curious to know the mechanism through which p53 is induced in response to C6. 
Nucleolar stress itself can induce p53, via disruption of the HDM2-p53 interaction that leads 
to stabilization of the p53 protein (Russo and Russo, 2017), but there are also indications 
that p53 protein synthesis can be induced when cap-dependent translation is perturbed 
(Harris et al., 2018). Because DNA damage can induce p53 at the levels of both synthesis 
and turnover, we first showed that C6 does not induce a robust DNA damage response, as 
measured by the accumulation of γ-H2AX foci (Figures S5C and S5D). Next, we performed 
CHX-chase assays to monitor the proteolytic turnover of p53 in response to C6. As a 
control, we compared the effects of C6 with those of nutlin-3, a small molecule inhibitor of 
the HDM2-p53 interaction (Nicolae et al., 2014). Here (Figure 4C), as expected, nutlin-3 
increased the stability of p53 in response to CHX treatment. Compound C6, in contrast, had 
no detectable effects on p53 turnover. The induction of p53 that we observe in response to 
WIN site inhibition, therefore, is unlikely to be due to an increase in the metabolic stability 
of the protein.
To monitor for the induction of p53 translation, we asked how C6 treatment altered the 
amount of TP53 mRNA on polysomes versus monosome fractions (Yang et al., 2006). Here, 
we found that C6 promoted an accumulation of polysome-associated mRNAs for TP53 and 
a p53 target gene, TP53IPN1 (Figure 4D). The increase in TP53 mRNA on the polysome 
fraction, amidst a backdrop of decreased translation (Figure 4A), strongly implies that WIN 
site inhibition induces p53 via a selective induction of TP53 mRNA translation.
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WIN Site Inhibitors Rapidly Displace WDR5 from Chromatin and Inhibit RPG Transcription
All of the studies of WIN site inhibitors to date have examined the transcriptional or 
epigenetic consequences of WIN site blockade over a relatively long time frame (e.g., >48 
h). The low temporal resolution of these studies makes it difficult to separate cause from 
effect, and thus to determine the primary mechanism of action of the compounds. We 
reasoned that the primary transcriptional effects of WIN site inhibitors should manifest 
early, and therefore, we looked at transcriptional and epigenetic changes that occur within a 
few hours of compound treatment.
To monitor transcription, we used precision nuclear run-on sequencing (PRO-seq) (Kwak et 
al., 2013; Zhao et al., 2016), a global nuclear run-on approach, to ask how the distribution of 
active RNA polymerases is altered across the genome soon after WIN site blockade. 
MV4:11 cells were treated with C3 for 0, 15, 30, or 60 min and PRO-seq performed to 
follow changes in the distribution of active RNA polymerases. This analysis (Figures 5A and 
5B) identified a set of 47 transcription units (45 loci) in which WIN site inhibition caused a 
significant decrease in gene body transcription. There were no instances in which C3 
promoted an increase in transcription. In general, transcriptional changes at these repressed 
genes were significant (padj =0.0007–10−28) and modest (1.5- to 2-fold), and most were 
captured at the 15-min time point, indicating that C3 acts quickly to influence transcriptional 
processes. Almost all of the genes repressed by compound treatment are bound by WDR5 
(Figure 5A), and a majority (~70%) encode ribosome subunits. Moreover, within the RPGs, 
we observed a consistent pattern of genes occupied by WDR5, scored as repressed by PRO-
seq, and scored as repressed in RNA-seq experiments (Figure S6A), indicating that these 
genes are a direct and persistent transcriptional target of WIN site blockade.
To look at accompanying epigenetic changes, we monitored histone H3K4 trimethylation, 
which is appropriate given that both C3 and C6 are potent inhibitors of MLL1 complex 
HMT activity (Table 1). After 4 h of C3 treatment, however—well after transcriptional 
effects are evident (Figure 5A)—there is little, if any, change in the H3K4me3 status of 
select WDR5-bound genes (Figure S6B). As a control in these experiments, WDR5 was 
examined under these same conditions, and we were surprised to see that C3 treatment 
resulted in a >10-fold reduction in WDR5 binding at all five loci (Figure 5C). These changes 
in chromatin binding were not due to changes in the levels of WDR5 (Figure S6C). 
Consistent with the ChIP results, treatment with C3 reduced the total amount of chromatin-
bound WDR5 (Figure 5D; “P3” fraction), with a commensurate increase in WDR5 in the 
soluble (S2) and solubilized nuclear fractions (S3). To determine whether displacement of 
WDR5 from chromatin is a bona fide consequence of WIN site blockade, we engineered 
HEK293 cells to express FLAG epitope-tagged WDR5; WT, or a mutant in which 
phenylalanine 133—which makes critical interactions with the guanidinium of the arginine 
in the WIN motif—is changed to alanine (F133A). These forms of WDR5 were expressed 
equally, and the F133A mutant retained the ability to interact with RBBP5 (Figure S6D). 
When we examined chromatin binding by ChIP, however, we could not detect binding of the 
F133A WDR5 mutant to any of the loci tested (Figure 3E). The parallel effects of chemical 
and genetic blockade of the WIN site reveal that a prominent role of this site is to link 
WDR5 to chromatin.
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Finally, we extended these analyses to our more potent compound C6 and performed ChIP-
seq for WDR5 in MV4:11 cells treated for 4 h with either C6nc or C6 (Figure 5F). 
Compound C6nc had little impact on WDR5 binding. Compound C6, in contrast, resulted in 
a robust decrease in all detectable WDR5 binding events, with no measurable effect on 
WDR5 levels (Figure S6C). Based on these data, we conclude that the primary mechanism 
of action of our WIN site inhibitors is to rapidly displace WDR5 from chromatin, resulting 
in a commensurate decrease in the expression of a subset of WDR5 target genes.
DISCUSSION
The discovery of small molecule inhibitors of epigenetic proteins not only opens new 
opportunities for drug discovery but also allows for the interrogation of the mechanisms 
through which these proteins work. Here, we discovered potent small molecules that bind 
tightly to the WIN site of WDR5 and used these to explore the impact of WIN site blockade 
on the interaction of WDR5 with chromatin, transcriptional patterns, and cellular functions. 
Our studies reveal that WDR5 is bound to a relatively small cohort of loci, enriched in a 
specific subset of ribosome protein genes. Chemical perturbation of the WIN site displaces 
WDR5 from these loci, resulting in a rapid and persistent decrease in the expression of 
WDR5-bound RPGs, induction of translational stress, increased p53 translation, and 
activation of p53-dependent apoptosis. These findings demonstrate that WDR5 is a major 
regulator of ribosome protein gene transcription and forecast that WIN site inhibitors could 
have broad utility for cancer treatment.
One of the major conclusions from this study is that the WIN site links WDR5 to chromatin. 
This conclusion is supported by findings with both C3 and C6 and with the F133A WDR5 
mutant, which is unable to bind WIN motif-containing peptides (Patel et al., 2008). 
Although the WIN site binds at least a half-dozen interaction partners (Guarnaccia and 
Tansey, 2018), none of these partners have been proposed to recruit WDR5 to chromatin. 
The ability of WIN site blockade to evict WDR5 from its target genes, however, supports the 
idea that WDR5 is linked to chromatin through the WIN site, either indirectly or by 
engaging a WIN motif in a chromatin-resident protein. If the latter is correct, then this 
protein may be one of the characterized WIN site binders, but as there are thousands of 
proteins encoded in the human genome that carry the core WIN motif (A-R-A/S/T), it is 
likely that the factor(s) responsible for tethering WDR5 to chromatin is yet to be identified. 
Clearly, a grasp of the complete repertoire of WIN site binders is needed to fully recognize 
the mechanism and utility of small molecule WIN site inhibitors.
Critical in defining the primary mechanism of action of WIN site inhibitors is to determine 
which genes are directly affected by WIN site blockade. Our experiments with both C3 and 
C6 clearly point to a specific subset of RPGs as targets of WIN site inhibition. The extensive 
overlap between RPGs identified as targets of C3 in PRO-seq and those identified as targets 
of C6 in RNA-seq reveals a highly consistent mode of action of these two compounds. The 
consistency in their mode of action is solidified by the fact that both C3 and C6 displace 
WDR5 from chromatin and by our observation that a distinct WIN site inhibitor, 
OICR-9429, shows the same selectivity in RPG inhibition. Coupled with the recurring and 
highly consistent binding of WDR5 to a select subset of RPGs in different cell types, we 
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conclude that these RPGs are a predominant biological target of WDR5 and thus of WDR5 
inhibitors.
The importance of ribosomes and altered ribosome biogenesis to cancer has long been 
known, but the links between WDR5 and RPGs have not previously been reported. The 
Cancer Dependency Map initiative (Tsherniak et al., 2017), which correlated results from 
~500 genome-wide loss-of-function screens, reported that 6 of the top 10 correlated 
dependency profiles for WDR5 are RPGs, supporting the notion that WDR5 is meaningfully 
connected to ribosome homeostasis. Hyperactive ribosome synthesis is a hallmark of many 
cancers (Pelletier et al., 2018), and WDR5 has the potential to mediate altered RPG 
expression in this context, either by its own overexpression (e.g., Chen et al., 2015; Dai et 
al., 2015; Tan et al., 2017) or by working with oncoproteins such as MYC (Carugo et al., 
2016; Thomas et al., 2015). What is difficult to reconcile, however, is why only a defined 
subset of RPGs are under the control of WDR5 and what this means for both normal cellular 
activities and altered ribosome function in cancer. It is possible that the specific RPGs that 
are regulated by WDR5 have some common property, as yet unknown, that requires their 
coordinated expression via WDR5. Alternatively, perhaps the biased distribution of WDR5 
across the RPGs acts as a nuclear sensor of oncogenic activity, an early surveillance 
mechanism that induces ribosome subunit imbalance—and triggers a pro-apoptotic stress 
response—when WDR5 (or factors that work through WDR5) levels rise in a cancer cell. 
Regardless of the significance of the WDR5-RPG connection, however, it creates an 
opportunity to induce a translational choke and trigger p53-dependent apoptosis in cancer 
cells, as discussed below.
The utility of WIN site inhibition in the context of MLLr cancers is well established, and our 
findings with C3 and C6 strengthen this connection. Exactly why MLLr cells are sensitive to 
WIN site blockade needs further study, but likely relates to the ability of MLL-fusion 
oncoproteins to induce the transcription of genes connected to ribosomal and nucleolar 
processes, which has recently been recognized as an important and distinct part of their 
transcriptional repertoire (Garcia-Cuellar et al., 2016). The discrepancy between the affinity 
of these inhibitors for WDR5 in vitro and the concentrations needed to engage WDR5 in 
cells and elicit a biological response demonstrates that additional strides need to be made to 
increase the permeability of these inhibitors and/or their ability to access WDR5 when it is 
complexed with other proteins. Nonetheless, the mechanism of action we describe for these 
compounds, which is likely shared by other WIN site inhibitors, does have important 
therapeutic implications that transcend MLLr cancers.
For example, the overexpression of WDR5 is reported in numerous malignancies, including 
leukemias (Ge et al., 2016), breast cancer (Dai et al., 2015), and bladder cancer (Chen et al., 
2015). For cancers with frank WDR5 overexpression, therefore, the ability of our inhibitors 
to displace WDR5 from chromatin predicts that the functional impact of WDR5 
overexpression in these cancers could be attenuated by pharmacological WIN site blockade. 
Moreover, the mechanism of p53 induction in response to WIN site inhibition, which is 
independent of changes in p53 protein stability, may also offer unique therapeutic 
opportunities, as this is different from the effects of inhibitors of the HDM2-p53 interaction, 
which have had mixed success in the clinic (Stegh, 2012).
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Although in this context WIN site inhibitors kill MLLr cells independent of changes in 
H3K4 methylation, we note that our WIN site compounds are potent inhibitors of MLL1-
driven HMT activity. The half-maximal inhibitory concentration (IC50) value for C6 is ~20 
nM compared to 320 nM for MM-401 (Cao et al., 2014), with at least a 250-fold window of 
selectivity for MLL1 over other MLL/SET complexes. The inhibition of MLL1-mediated 
H3K4 methylation has been shown to be a viable strategy for killing cancer cells that 
express mutant forms of C/EBPa (Grebien et al., 2015) and p53 (Zhu et al., 2015). In these 
cancers, as well as others that are MLL1 dependent, the ability of these inhibitors to 
specifically target the HMT activity of MLL1 complexes may be exploited for therapeutic 
gain.
Perhaps the most intriguing application of WIN site inhibitors, however, relates to their 
ability to inhibit RPG transcription. The concept of targeting ribosome biosynthesis has 
gained momentum in recent years as a viable strategy to treat cancer (Pelletier et al., 2018), 
and may hold promise in other diseases of ribosome dysfunction, such as myelodysplastic 
syndrome (Rinker et al., 2016). Most of the successes in this area have centered on the 
inhibition of ribosomal RNA transcription (Bruno et al., 2017). While these strategies 
progress, a complementary approach of targeting RPG synthesis via WIN site blockade 
could have value. It is possible, for example, that the specific pattern of RPG imbalance 
caused by WIN site inhibitors has advantages over rRNA inhibition. As opposed to a general 
inhibition of ribosome biogenesis, WIN site inhibitors will only directly affect the 
expression of those RPGs to which WDR5 is bound. Thus far, this group of RPGs appears to 
be conserved, and if this conservation withstands further challenge, it will be possible to 
predict which RPGs will respond to WIN site blockade. It is clear that ribosome dysgenesis 
in cancer cells is not random and that specific patterns of RPG alterations occur that can 
distinguish normal from malignant cells and one type of cancer from another (Dolezal et al., 
2018). By systematic analysis of the relationship between altered RPG expression and 
cellular sensitivity to WIN site inhibition, it may be possible to develop targeted WIN site 
inhibitor therapies matched to specific patterns of ribosome protein gene alterations in 
cancer patients.
STAR★METHODS
CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be 
fulfilled by the Lead Contact, William Tansey (william.p.tansey@vanderbilt.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell lines—MV4:11 (male), K562 (female), HL60 (female), Molm13 (male), HEL (male), 
SET-2 (female), NOMO-1 (female), GDM-1 (female), and RN2 (female) cell lines were 
cultured in RPMI-1640 media with 10% FBS. THP-1 (male) cells were grown in 
RPMI-1640 media with 0.05 mM 2-mercaptoethanol and 10% FBS. MA93 Ras (male) and 
MA93 FLT3/ITD (male) cells were grown in IMDM media with 20% FBS. MA93 (male) 
cells were grown in IMDM media with 20% FBS, and 10 ng/mL recombinant human 
SCF/TPO/FLT3L/IL3/IL6. MONO-MAC-6 (male) cells were grown in RPMI with 10% 
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FBS, non-essential amino acids and OPI media supplement. HEK293T (female) cells, and 
their derivatives, were maintained in DMEM supplemented with 10% FBS. All media was 
supplemented with 100 IU/ml Penicillin and 100 μg/ml streptomycin. All cell lines were 
cultured at 37°C with 5% CO2 and split every 2–4 days; suspension cells were maintained at 
a cell density of between 1 3 105 and 1 × 106 cells/ml.
METHOD DETAILS
Protein Expression and Purification—Human WDR5 (aa: 22–334) was cloned into a 
modified pET vector (pBG104) with a 6xHis-SUMO tag present at the N terminus. The 
plasmid was then transformed into E. coli BL21 (DE3) cells. One hundred milliliters of LB 
starter was used to inoculate a 10 l fermentation culture (BioFlo 415, New Brunswick 
Scientific), grown at 37°C. Fermentation growth media contained KH2PO4 (4 g/L), K2HPO4 
(6 g/L), Na2SO4 (2 g/L), K2SO4 (1 g/L), NaCl (0.5 g/L), Yeast Extract (5 g/L), glycerol (2 
ml/L), Antifoam (0.2 ml/L), 5% LB medium, glucose (25 g/L), MgCl2 (2 mM), CaCl2 (0.1 
mM), NH4Cl (2.5 g/L), and Kanamycin (50 mg/ml). When the cell density reached OD600 = 
2.0, the temperature was lowered to 30°C, and WDR5 expression induced by treatment with 
1 mM isopropyl-b-D-thiogalactoside (IPTG) overnight. Cell pellets were collected, 
dissolved in lysis buffer containing 1XPBS plus 300 mM NaCl, 20 mM imidazole, 5 mM 
BME, and 10% glycerol, and lysed by homogenization (APV-2000, APV). The lysate was 
cleared by centrifugation, filtered, and then applied to the Ni-column (140 mL, ProBond, 
Invitrogen). Bound protein was eluted using an imidazole gradient (0–300 mM). The His-
SUMO-tag was cleaved by SUMO protease during dialysis and subsequently eliminated 
through a second Ni-column. WDR5 protein was then purified by size-exclusion 
chromatography (HiLoad 26/60, Superdex 75, GE Healthcare) using crystallization buffer 
consisting of 20 mM HEPES, pH 7.0, 250 mM NaCl, and 5 mM DTT. The purity of protein 
was checked using SDS–PAGE. Purified WDR5 was then concentrated to 10 mg/mL, and 
was stored at −80°C.
Protein Crystallization, Data Collection, and Structure Refinement—WDR5 apo- 
and co-crystals were obtained at 18°C using the hanging drop method. The crystallization 
condition was 0.1 M Bis-Tris pH 6.0, 0.2 M ammonium acetate, 28% to 32% PEG3350. A 
soaking method was applied for some of the compounds using WDR5 apo-crystals. Crystals 
were flash frozen directly in liquid nitrogen. Diffraction data were collected on the Life 
Sciences Collaborative Access Team (LS-CAT) 21-ID-D and G beamlines at the Advanced 
Photon Source (APS) at Argonne National Laboratory. Diffraction data were indexed, 
integrated, and scaled using HKL2000 (Otwinowski and Minor, 1997). Molecular 
replacement was applied using Phaser44 as implemented in CCP4.45 (Winn et al., 2011) 
using a published structure (PDB code 3EG6). Refinement of the structural models was 
performed using PHENIX (Adams et al., 2002) along with rounds of manual model building 
in COOT (Emsley and Cowtan, 2004). All structure images were prepared with PyMOL. A 
summary of the final refinement statistics for structures including compounds C1–6 can be 
found in the Table S2.
FPA and TR-FRET Competition Assays—Fluorescein isothiocyante (FITC) labeled 
MLL peptide (FITC-GSARAEVHLRKS) and 10-mer-Thr-FAM (ARTEVHLRKS-(Ahx-
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Ahx)(Lys-(5-FAM))) (Karatas et al., 2010) were purchased from GeneScript and used 
without additional purification. Anisotropy, fluorescence, and TR-FRET emissions were 
recorded on a BioTek Cytation 3 instrument.
For the FITC-MLL FPA peptide assays, FITC-MLL peptide (FITC-GSARAEVHLRKS) 
was used at 50 nM, while WDR5 was added at the Kd value of the protein:peptide 
interaction (WDR5–WIN Kd = 2.5 μM). Stock compounds were dispensed in 384-well 
source plates as 30 mM solutions in DMSO. An Echo Liquid Handler was used to distribute 
the compounds to the assay plates (384-well, black, flat-bottom; Greiner) in a 10-point, 3-
fold dilution, scheme in a final volume of 50 μL using a top concentration of 250 mM. Both 
the top concentration and the dilution scheme were adjusted to fit the potency of the 
compounds to a lower Ki limit of ~1 μM. For the FITC MLL assay, 2.5 μM WDR5 and 50 
nM FITC-MLL peptide, in an assay buffer containing 1X Phosphate Buffered Saline (pH 
6.0), 300 mM NaCl, 0.5mM TCEP, and 0.1% CHAPS, were added to all compound-
containing wells. To columns 1 and 23 (positive control, 100% inhibition) 2 μl of 50 nM 
FITC-MLL peptide alone in assay buffer was added. The assay performed with an average 
Z’ value of 0.5 and was tolerant up to 5% DMSO. For compounds with an IC50 < 2.0 μM 
and Ki < 1 μM, the 10-mer-Thr-FAM probe and FPA protocol described below was used for 
enhanced sensitivity.
For the 10-mer-Thr-FAM peptide TR-FRET assay, LanthaScreen Elite Tb-anti His antibody 
(Tb-Ab) was purchased from Thermo-Fisher and used at 1 nM. The 10-mer-Thr-FAM 
peptide was used at 150 nM, while WDR5-His-SUMO tag protein was used at 2 nM. The 
working assay buffer composition was modified to pH 7.2 (1X Phosphate Buffered Saline, 
300 mM NaCl, 0.5 mM TCEP, 0.1% CHAPS). Stock compounds were dispensed to a white, 
flat-bottom OptiPlate plate (PerkinElmer) using an Echo Liquid Handler. A 10-point, 5-fold 
dilution scheme with a top concentration of 5 μM (0.003 nM low concentration) was used 
with a final volume of 20 μl. Both the top concentration and the dilution scheme was 
adjusted to fit the anticipated potency of the compounds. Using the above probe 
concentration and assay conditions, the calculated lower Ki limit was ~0.060 ± 0.020 nM. 
Positive control wells (0% displacement) consisted of 10-mer-Thr-FAM probe and 
WDR5/Tb antibody mix occupying columns 2 and 24, while negative control wells (100% 
displacement) consisting of the protein/terbium antibody mix alone occupy columns 1 and 
23. The assay performed with an average Z’ value of 0.7 and was found to be tolerant to up 
to 5% DMSO.
For IC50 determinations, plates were covered, shielded from light, and incubated for 1h at 
room temperature with rocking. For the FPA assay measurements, anisotropy was measured 
using an excitation wavelength of 480 nm and an emission wavelength of 535 nm. For the 
TR-FRET assay, measurement plates were excited at a wavelength of 340 nm, and emission 
wavelengths of 495 and 520 nm were used. The ratio of the 520/495 wavelengths were used 
to assess the degree of the FRET signal and resulting peptide displacement. TR-FRET plate 
positive control wells include columns 2 and 24 containing 10-mer-Thr-FAM peptide, His-
SUMOWDR5, and Tb-anti-His antibody to measure maximum signal from the FRET 
response. The change in anisotropy (FPA) or 520 / 495 emission ratio (TR-FRET) was used 
to calculate an IC50 (inhibitor concentration at which 50% of the bound peptide is displaced) 
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by fitting the inhibition data using XLFit software (Guilford, UK) to single-site binding 
model. This was converted into a binding inhibition/displacement constant (Ki) using the 
formula (Nikolovska-Coleska et al., 2004):
Compound Ki = [I]50/ [L]50/Kd
pep + [P]0/Kd
pep + 1
where [I]50 is the concentration of the free inhibitor at 50% inhibition, [L]50 is the 
concentration of the free labeled ligand at 50% inhibition, [P]0 is the concentration of the 
free protein at 0% inhibition, and Kdpep represents the dissociation constant of the FITC-
MLL or 10-mer-Thr-FAM probe.
Surface Plasmon Resonance—SPR measurements were performed at XTAL 
Biosciences with compounds and purified WDR5 provided by us. SPR measurements were 
performed using a BiOptix 404pi enhanced surface plasmon resonance (eSPR) instrument. 
Compounds C3 and C6 were prepared as DMSO soluble stock solutions at 30 mM DMSO. 
His-SUMO-WDR5(22–334) protein was placed onto two channels (in parallel). The 
conditioned biosensor NTA-biosensor chip was first charged with Ni2+ to allow for pre-
concentration and then chemically activated with EDC/NHS. His-tagged protein ligand at 
100 nM in running buffer (PBS, 2 mM DTT, 50 μM EDTA, 0.05% Tween-20, with no 
DMSO) was covalently attached to the dextran surface via amide coupling at 5 μL/min for 
100 s. The His-SUMOWDR5(22–334) protein (PBS + 2mM DTT buffer) was then loaded 
onto channel 3 and channel 4 of the biosensor chip at 7,000 RU, leaving channels 1 and 2 
unbound as reference. A solution of 1 M ethanolamine was injected for 1200 s at 20 μL/min 
to block any free reactive carboxyls across all channels. For analyte binding, the BiOptix 
was run in 2×2 mode. Analyte compounds C3 and C6 were first passed over one of these 
reference channels before coming into contact with the bound protein on channels 3 or 4. An 
8-point, 3-fold serial dilution assay was performed in duplicate for compounds C3 and C6 
starting at 100 nM and going down to 90 pM. DMSO stocks of compounds were diluted in 
running buffer with a final 1% DMSO. Association times were increased from 240 to 800 s 
by decreasing the flow rate to 30 μL/min. An 800 s dissociation phase followed. Saturation 
was achieved in order to measure steady state binding as well as kinetics. Buffer blanks were 
inserted after every forth injection. A series of five DMSO standards between 0.5% and 
1.5% were included with each run to correct for bulk refractive index. Sensorgrams were 
analyzed using Scrubber 2 software with a double reference to determine the interaction 
parameters KD, kon, and koff. The reference channel was first subtracted from the ligand 
channel. Next the bulk shift was corrected for using the DMSO standards included with each 
run.
The internal blank injections were then averaged and subtracted from compound injections. 
Binding data was fit to a 1:1 Langmuir model. Each sensorgram is fit to a standard scale.
Histone Methyltransferase Assays—HMT inhibition activity assays were performed 
at Reaction Biology Corp. Details are under “Critical Commercial Assays” in the Key 
Resources Table.
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Compound Synthesis and Characterization—Compounds C1 and C4 are were 
purchased from commercial vendors and were derived as hits from the Vanderbilt Fragment 
Library. Compound 1 (CAS: 1334103-40-0), Compound 4 (CAS: 876709-30-7).
Compound C2 – N-(1-(3-Chlorophenyl)ethyl)-3-(((4,5-dihydro-1H-imidazol-2-
yl)amino)methyl)benzamide: 3-(N-Boc-aminomethyl)benzoic acid (251 mg, 1.0 mmol) 
and DIPEA (522 μL, 3.0 mmol) were taken in CH2Cl2 (5 mL) and cooled to 0°C. HATU 
(570 mg, 1.5 mmol) was added and the mixture stirred for 30 mins before the addition of 1-
(3-chlorophenyl)ethanamine (156 μL, 1.1 mmol). The solution was allowed to warm to r.t. 
and stirred for 16 h. Upon completion, the mixture was diluted with CH2Cl2 (5 mL) and 
washed with H2O (10 mL), concentrated, and purified by flash column chromatography (12 
g, 0 – 40% EtOAc in hexanes) to afford the intermediate tert-Butyl (3-((1-(3-
chlorophenyl)ethyl)carbamoyl)benzyl)carbamate as a colorless solid (228 mg, 0.59 mmol, 
59%). This was dissolved in CH2Cl2 (3 mL), TFA (1.5 mL) was added and the mixture was 
stirred at r.t. for 2 h. The mixture was concentrated in vacuo to afford the crude amine 
intermediate as a TFA salt (assumed quantitative). The amine was dissolved in anhydrous 
THF (2 mL) under an inert atmosphere and 2-methylthio-2-imiazoline hydroiodide (120 mg, 
0.49 mmol) and DIPEA (209 μL, 1.2 mmol) were added. The mixture was stirred at 40°C 
for 16 h, venting through a scrubber of NaOH. Upon completion, the solution was 
concentrated, taken in EtOAc and washed with NaOH (2 M), brine, and purified by 
preparative HPLC. The combined fractions were re-dissolved in EtOAc and washed with sat. 
aq. K2CO3 and dried (MgSO4) to afford C2 as the free base. 1H NMR (600 MHz, MeOH-
d4) H 7.83 – 7.79 (m, 1H), 7.80 – 7.76 (m, 1H), 7.52 – 7.47 (m, 2H), 7.42 – 7.38 (m, 1H), 
7.33 – 7.29 (m, 2H), 7.26 – 7.22 (m, 1H), 5.20 (q, J = 7.1 Hz, 1H), 4.45 (s, 2H), 3.71 (s, 4H), 
1.56 (d, J = 7.1 Hz, 3H); LCMS (ESI) tR = 0.85 min, m/z = 357.3 [M+H]+; ≥ 95% (215, 254 
nm); HMRS (ESI-TOF) calculated for C19H22ClN4O = 357.1477 [M+H]+, observed 
357.1477.
Compound C3 – 3-(((4,5-dihydro-1H-imidazol-2-yl)amino)methyl)-N-(3,5-
dimethoxybenzyl)-4-fluorobenzamide: To a solution of methyl 4-fluoro-3-methylbenzoate 
(5.0 g, 29.7 mmol) in CCl4 (60 mL) was added NBS (5.5 g, 30.9 mmol) and AIBN (0.20 g, 
1.20 mmol). The mixture was heated to reflux for 18 h, then cooled, filtered and the filtrate 
was concentrated. The crude material was purified by flash column chromatography to 
afford methyl 3-(bromomethyl)-4-fluorobenzoate (3.6 g, 14.6 mmol, 49%). A portion of the 
brominated intermediate (2.0 g, 8.10 mmol) was dissolved in a 90% MeOH/water solution 
(40 mL) and to which sodium azide (0.78 g, 12.1 mmol) was added. The mixture was then 
heated to reflux for 2 h. The solution was cooled, concentrated, re-dissolved in CH2Cl2, and 
extracted with H2O. The organic phase was dried (MgSO4) and concentrated to afford the 
crude azide intermediate. The intermediate was dissolved in a solution of THF (20 mL), 
MeOH (5 mL) and water (3 mL) and then treated with LiOH (2.0 M, 2.2 mL, 4.4 mmol) for 
2 h at r.t.. The solvent was removed under reduced pressure, diluted with water, and acidified 
with HCl (1 N) to a pH = 1. The resulting solid was collected by filtration, washed with 
water, and dried under high vacuum to afford 3-(azidomethyl)-4-fluorobenzoic acid (1.58 g, 
quant.), which was used without further purification. A portion of the benzoic acid 
intermediate (195 mg, 1.0 mmol) in DMF (4 mL) was cooled to 0°C before the addition of 
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DIPEA (435 mL, 2.5 mmol) and HATU (399 mg, 1.05 mmol). After 5 mins, (3,5-
dimethoxyphenyl)methanamine (166 μL, 1.1 mmol) was added. The mixture was stirred for 
18 h, then concentrated. The crude mixture was dissolved in ethyl acetate, extracted with 
water and dried over MgSO4, filtered, and concentrated. The crude amide intermediate was 
used without further purification. A solution of crude 3-(azidomethyl)-N-(3,5-
dimethoxyphenyl)-2-fluorobenzamide (370 mg, 1.1 mmol) in EtOH (20 mL) was treated 
with Raney-Ni (0.1 g) and then stirred under an atmosphere of H2 for 2 h. The catalyst was 
removed by filtration, and the solvent was removed under reduced pressure. The crude 
mixture was then dissolved in pyridine (5 mL), and 2-methylthio-2-imidazoline hydroiodide 
(0.31 g, 1.28 mmol) was added. This mixture was heated under mW irradiation at 125°C for 
1 h. The solvent was removed under reduced pressure, and the material was purified by 
preparative HPLC. The combined fractions of product were dissolved in EtOAc and washed 
with sat. aq. K2CO3. The organic layer was dried (MgSO4), and the solvent was removed 
under reduced pressure to afford C3 as the free base (220 mg, 0.57 mmol, 57%). 1H NMR 
(600 MHz, MeOH-d4) δH 7.92 – 7.85 (m, 2H), 7.26 (dd, J = 9.9, 8.4 Hz, 1H), 6.50 (d, J = 
2.2 Hz, 2H), 6.37 (t, J = 2.2 Hz, 1H), 4.51 (s, 2H), 4.49 (s, 2H), 3.75 (s, 6H), 3.73 (s, 4H); 
19F NMR (376 MHz, MeOH-d4) δF 115.5; 13C NMR (151 MHz, MeOH-d4) δC 167.2, 
163.4, 161.8, 161.1, 160.0, 140.9, 130.9, 130.9, 128.9 (d, J = 9.2 Hz), 128.7 (d, J = 4.9 Hz), 
124.0, 123.9, 115.4 (d, J = 22.1 Hz), 105.1, 98.4, 54.3, 43.3, 42.8, 40.1, 40.0; LCMS (ESI) 
tR = 0.90 min, m/z = 387.1 [M+H]+; ≥ 95% (215, 254 nm); HMRS (ESI-TOF) calculated for 
C20H24FN+4O3 = 387.1827 [M+H]+, observed 387.1828.
Compound C3nc – 3-(((4,5-dihydro-1H-imidazol-2-yl)amino)methyl)-N-(3,5-
dimethoxybenzyl)-2-fluorobenzamide: C3nc was synthesized following the same 
synthetic route as used for Compound 3, starting from methyl 3-(bromomethyl)-2-
fluorobenzoate. 1H NMR (600 MHz, MeOH-d4) δH 7.66 (td, J = 7.5, 1.8 Hz, 1H), 7.51 (td, J 
= 7.5, 1.8 Hz, 1H), 7.30 (t, J = 7.5 Hz, 1H), 6.53 (d, J = 2.3 Hz, 2H), 6.38 (t, J = 2.3 Hz, 1H), 
4.51 (br s, 4H), 3.76 (s, 6H), 3.73 (s, 4H); 19F NMR (376 MHz, MeOH-d4) δF 121.6; 13C 
NMR (151 MHz, MeOH-d4) δC 165.3, 161.2, 159.9, 158.6, 157.0, 140.6, 131.5 (d, J = 4.3 
Hz), 129.8 (d, J = 2.9 Hz), 124.5 (d. J = 4.3 Hz), 124.4, 124.3, 123.9, 123.8, 105.0, 98.6, 
54.3, 43.2, 42.8, 40.1 (d, J = 5.3 Hz); LCMS (ESI) tR = 0.70 min, m/z = 387.3 [M+H]+; ≥ 
95% (215, 254 nm); HMRS (ESI-TOF) calculated for C20H24FN4O3 = 387.1827 [M+H]+, 
observed 387.1831.
Compound C5 – 3-((1H-Imidazol-1-yl)methyl)-N-(3,5-dichlorobenzyl)benzamide: 3-
(Chloromethyl)benzoyl chloride (142 μL, 1.0 mmol) was dissolved in CH2Cl2 (5 mL) and 
cooled to 40°C in an acetonitrile/dry-ice bath before the addition of DIPEA (348 mL, 2.0 
mmol) and 3,5-dichlorobenzylamine (133 μL, 1.0 mmol). The mixture was stirred for 1 h, 
allowing to warm to 0°C, then concentrated in vacuo, and re-dissolved in THF (5 mL). In a 
separate vial imidazole (82 mg, 1.2 mmol) and NaH (60% dispersion in mineral oil, 100 mg, 
2.5 mmol) were taken in THF (2.5 mL) and stirred for 30 mins. The crude aryl chloride was 
added into the flask and heated to reflux for 18 h. The cooled mixture was diluted with 
EtOAc and washed with sat. aq. NH4Cl, brine and purified by flash column chromatography 
(12 g, 0%–10% MeOH in CH2Cl2) to afford the title compound as a pale-yellow solid (188 
mg, 0.52 mmol, 52%). 1H NMR (600 MHz, MeOH-d4)H 7.80 (dt, J = 7.7, 1.5 Hz, 1H), 7.79 
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– 7.75 (m, 2H), 7.48 (t, J = 7.7 Hz, 1H), 7.42 (dt, J = 7.9, 1.4 Hz, 1H), 7.32 (t, J = 1.9 Hz, 
1H), 7.30 (d, J = 1.9 Hz, 2H), 7.13 (q, J = 1.4 Hz, 1H), 6.99 (t, J = 1.4 Hz, 1H), 5.29 (s, 2H), 
4.52 (s, 2H); 13C NMR (151 MHz, MeOH-d4) δC 168.3, 143.0, 137.7, 137.3, 134.8, 134.6, 
130.6, 128.9, 128.1, 128.1, 126.7, 126.6, 126.4, 125.8, 119.5, 119.5, 49.8, 42.2; LCMS (ESI) 
tR = 0.86 min, m/z = 360.3 [M+H]+ (dichloro splitting visible); ≥ 95% (215, 254 nm); 
HMRS (ESI-TOF) calculated for C18H16Cl2N3O = 360.0665 [M+H]+, observed 360.0645.
Compound C6 – N-(3,4-Dichlorobenzyl)-3-(6-fluoro-2-methylpyridin-3-yl)-5-((2-
imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)benzamide: Argon gas was 
bubbled into a mixture of methyl 3-bromo-5-(hydroxymethyl)benzoate (7.50 g, 30.6 mmol), 
K2CO3 (10.69 g, 72.5 mmol) and 80% 1,4 dioxane / water (665 mL) for 5 min before the 
addition of Pd(PPh3)4 (2.68 g, 2.32 mmol) and (6-fluoro-2-methylpyridin-3-yl)boronic acid 
(6.4 g, 41.5 mmol). The reaction was heated to 80°C for 6 h, then the solvent was removed 
under reduced pressure. The crude mixture was dissolved in CH2Cl2, extracted with water, 
dried with MgSO4, filtered, concentrated and purified by flash column chromatography to 
afford methyl 3-(6-fluoro-2-methylpyridin-3-yl)-5-(hydroxymethyl)benzoate (7.19 g, 26.1 
mmol, 83%). This was dissolved in THF (200 mL) / MeOH (50 mL) / water (50 ml) and 
stirred with LiOH (1.13 g, 54.0 mmol) for 6 h. The mixture was concentrated, diluted with 
water, and the pH was adjusted to ~1 with HCl (1N). The resulting solid was collected by 
filtration, washed with water, and dried under vacuum to afford 3-(6-fluoro-2-
methylpyridin-3-yl)-5-(hydroxymethyl)benzoic acid (6.20 g, 23.7 mmol, 91%). A portion of 
the benzoic acid intermediate (4.0 g, 15.3 mmol) in DMF (70 mL) was treated with Et3N 
(6.30 mL, 45.9 mmol) and cooled to 0°C in an ice/water bath. The mixture was treated with 
EDC (3.0 g, 16.1 mmol), HOBT (2.46 g, 16.1 mmol), stirred for 5 mins, and then treated 
with (3,4-dichlorophenyl)methanamine (2.96 g, 16.8 mmol) for 18 h. The DMF was 
removed under reduced pressure, and the crude mixture was dissolved in EtOAc, extracted 
with water, dried over MgSO4, filtered, concentrated and purified by flash column 
chromatography to afford N-(3,4-Dichlorobenzyl)-3-(6-fluoro-2-methylpyridin-3-yl)-5-
(hydroxymethyl)benzamide (3.87 g, 9.23 mmol, 60%). This intermediate was dissolved in 
CH2Cl2 (100 mL) / toluene (200 mL) cooled to 0°C in an ice/water bath and treated drop-
wise with PBr3 (1N, 9.7 mL, 9.7 mmol), upon complete addition the mixture was stirred for 
18 h. The reaction mixture was treated with water and NaHCO3 (s) until a basic pH was 
obtained. The organic layer was separated, washed with water, dried over MgSO4, filtered, 
concentrated and purified by flash column chromatography to afford 3-(bromomethyl)-N-
(3,4-dichlorobenzyl)-5-(6-fluoro-2-methylpyridin-3-yl)benzamide (2.81 g, 5.83 mmol, 
63%). The bromo intermediate, DIPEA (2.55 mL, 14.5 mmol), and 1-methyl-1H-
imidazol-2-amine (1.13 g, 11.60 mmol) were taken in MeCN (150 mL) and heated to 80°C 
for 18 h. The reaction was cooled, concentrated, and purified by reverse-phase HPLC. The 
combined fractions of product were dissolved in EtOAc and washed with sat. aq. K2CO3. 
The organic layer was dried (MgSO4), and the solvent removed under reduced pressure to 
afford C6 (1.79 g, 3.70 mmol, 63%). 1H NMR (600 MHz, MeOH-d4) δH 7.83 – 7.77 (m, 
3H), 7.50 (d, J = 2.1 Hz, 1H), 7.47 (d, J = 8.3 Hz, 1H), 7.44 (t, J = 1.7 Hz, 1H), 7.28 (dd, J = 
8.3, 2.1 Hz, 1H), 6.98 (dd, J = 8.4, 2.8 Hz, 1H), 6.89 (d, J = 2.6 Hz, 1H), 6.86 (d, J = 2.5 Hz, 
1H), 5.19 (s, 2H), 4.54 (s, 2H), 3.49 (s, 3H), 2.38 (s, 3H); 19F NMR (376 MHz, MeOH-d4) 
δF 72.2; 13C NMR (151 MHz, MeOH-d4) δC 167.5, 163.1, 161.5, 154.5, 147.2, 143.1 (d, J = 
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8.2 Hz), 139.7 (d, J = 26.2 Hz), 135.9, 135.2, 131.9, 131.0, 130.6, 130.3, 129.3, 127.5, 
127.2, 125.7, 117.0, 115.0, 106.5 (d, J = 37.1 Hz), 42.2, 31.7, 21.3; LCMS (ESI) tR = 0.91 
min, m/z = 498.3 [M+H]+ (dichloro splitting visible); ≥ 95% (215, 254 nm); HMRS (ESI-
TOF) calculated for C25H23Cl2FN5O = 498.1258 [M+H]+, observed 498.1266.
Compound C6nc – N-(3,4-dichlorobenzyl)-3-(6-fluoro-2-methylpyridin-3-yl)-4-((2-
imino-3-methyl-2,3-dihydro-1H-imidazol-1-yl)methyl)benzamide: Compound C6nc was 
synthesized following the same synthetic route as for Compound 6, starting from methyl 3-
bromo-4-(hydroxymethyl)benzoate. 1H NMR (600 MHz, MeOH-d4) δH 8.00 (dd, J = 8.1, 
2.0 Hz, 1H), 7.74 (d, J = 1.9 Hz, 1H), 7.59 (t, J = 8.2 Hz, 1H), 7.52 – 7.49 (m, 2H), 7.47 (d, J 
= 8.3 Hz, 1H), 7.28 (dd, J = 8.3, 2.1 Hz, 1H), 6.97 (dd, J = 8.2, 2.6 Hz, 1H), 6.86 (d, J = 2.6 
Hz, 1H), 6.56 (d, J = 2.6 Hz, 1H), 4.88 (s, 2H), 4.54 (s, 2H), 3.44 (s, 3H), 2.19 (s, 3H); 19F 
NMR (357 MHz, MeOH-d4) δF −71.0; 13C NMR (151 MHz, MeOH-d4) δC 167.3, 163.5, 
161.9, 155.2 (d, J = 13.7 Hz), 146.1, 142.6 (d, J = 8.0 Hz), 139.6, 138.4, 135.7, 134.8, 131.9, 
131.2 (d, J = 4.6 Hz), 130.6, 130.2, 130.2, 129.5, 129.4, 129.3, 127.7, 127.1, 117.3, 114.6, 
106.4 (d, J = 37.1 Hz), 42.2, 31.7, 21.0; LCMS (ESI) tR = 0.93 min, m/z = 498.3 [M+H]+ 
(dichloro splitting visible); ≥ 95% (215, 254 nm); HMRS (ESI-TOF) calculated for 
C25H23Cl2FN5O = 498.1258 [M+H]+, observed 498.1275.
Proliferation Assays—Cell proliferation was assayed using the Promega CellTiter-Glo 
Luminescent Kit. White, opaque, flat-bottomed 96-well plates were used. 5,000 cells were 
seeded per well for all cell lines, except 2,000 cells were seeded for MA93, MA93Ras, and 
MA93 FLT3/ITD to prevent overgrowth. Cells were treated with 0.1% DMSO vehicle only 
and at least five two-fold dilutions of WDR5 inhibitors with a top concentration of 50 μM. 
Final DMSO concentration was 0.1% in all compound treatment experiments. Each 
concentration of inhibitor was tested in triplicate wells and at least two biological replicates 
were performed. The total volume of cells with inhibitor was 100 μl per well. 200 μl of 
sterile PBS was added to all of the empty wells around the edge of the plate to prevent 
evaporation. Plates were incubated at 37°C for 72 hours. After 72 hours, the plates were 
allowed to reach room temperature before adding 50 μl of CellTiter-Glo reagent per well. 
Plates were incubated at room temperature, covered from light, for 30 minutes before the 
luminescence was measured using the CellTiter-Glo protocol on a GloMax plate reader. 
MTS assay (Promega CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay kit) 
was used to measure proliferation of RN2 cells. 2,500 cells were seeded into clear, flat-
bottomed 96-well plates and treated with inhibitors as stated above. After a 72-hour 
incubation, 20 μl of MTS solution was added per well and plates were incubated at 37°C for 
1.25 hours, then absorbance at 490 nm measured using a Bio-Rad iMark Microplate reader. 
For both CellTiter-Glo and MTS assays, the raw luminescence values were normalized to 
the DMSO vehicle only wells and PRISM software was used to generate GI50 values. Error 
bars on proliferation curves represent standard errors of the mean.
Growth and Viability Time Course—MV4:11 cells were plated at a density of 1 × 105 
cells/ml and treated with 0.1% DMSO only, 2 μM C6 or 2 μM C6nc. After 1, 2, 3, and 6 
days, cells were stained with trypan blue and counted using an automated cell counter. 
Viability and cell density was measured three times for each sample at each time point, then 
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averaged. On day 3, cells were spun down and resuspended in fresh media with fresh 
compound added. DMSO and C6nc-treated cells were replated to 1 × 105 cells/ml to prevent 
overgrowth. The time course was repeated with three biological replicates and error bars 
represent the standard error of the mean.
Cellular Thermal Shift Assay (CETSA)—CETSA was performed as described (Jafari et 
al., 2014). To determine the melting temperature of WDR5, K562 or MV4:11 cells were 
dispensed into PCR tubes at a density of ~1,000,000 cells/tube in 99 μl of DMEM. One 
microliter of DMSO was added to each tube and the cell suspension mixed by vortexing. 
Cells were then subjected to 3 minutes of heat in a 96-well thermal cycler at temperatures of 
46, 50, 54, 58, 62, 66, 70, 74, 78, 82, 86, and 90°C. Immediately after heating, cells were 
snap frozen in a CoolSafe Chamber (USA Scientific) surrounded by dry ice. To perform the 
isothermal dose-response of compounds against WDR5, K562 or MV4:11 cells were 
dispensed into PCR tubes at a density of ~1,000,000 cells/tube in 99 μl of DMEM. One 
microliter of compound, or DMSO, was added to each tube, mixed by vortexing, and 
incubated at 37°C for one hour. Cells were then heated at 79°C for 3 minutes in a 96-well 
thermal cycler. Immediately after heating, cells were snap frozen prior to lysate preparation. 
To prepare cell lysates, frozen cells were subjected to six rapid freeze-and-thaw cycles. After 
the first thaw, 1 μl of protease inhibitor cocktail (Sigma) was added to the cell lysates. Cell 
lysates were centrifuged at 4°C and 20,000 × g for 20 minutes. Samples were prepared by 
transferring 60 μl of supernatant into 20 μl of NuPAGE 4X LDS sample buffer 
(ThermoFisher) with 5 μl NuPAGE Sample Reducing Agent (10X) (ThermoFisher) and then 
heated for 15 minutes at 95°C. Note that in this experiment, cells without the 3-minute 
heating served as 100% stabilization and used for normalization purpose. Protein lysates 
were separated on a NuPAGE Novex 4%–12% Bis-Tris gel (ThermoFisher) and transferred 
onto PVDF membrane using an iBlot 2 Dry Blotting System (ThermoFisher). Membranes 
were blocked overnight with 5% nonfat dry milk (BIO-RAD) in PBST–Phosphate Buffered 
Saline (ThermoFisher) with 0.5% Tween-20 (Sigma). Membranes were then incubated for 1 
hour with 1:1,000 of rabbit monoclonal anti-WDR5 (D9E1I) antibody, washed three times 
for 15 minutes in PBST, incubated with 1: 1,000 anti-rabbit HRP linked IgG. After washing 
three times for 15 minutes in PBST, blots were incubated with SuperSignal West Dura 
Extended Duration Substrate (ThermoFisher). The chemiluminescence signals were 
captured by BIO-RAD CHEMDOC Imaging System, quantified by ImageQuant TL (GE 
Healthcare) and analyzed using Prism (GraphPad). Error bars on proliferation curves 
represent standard errors of the mean. Two independent biological replicates were 
performed.
Quantifying Relative Protein Synthesis Rates—Protein synthesis rates were 
measured by pulsing cells with O-propargyl-puromycin (OPP) (Signer et al., 2014). Briefly, 
MV4:11 cells were treated for 1, 2, 3 or 6 days with 2 μM of C6nc, 2 μM C6 or 0.1% DMSO 
vehicle control. At each time point, 2 million cells were collected per sample and pulsed 
with 50 μM OPP for 1 hour at 37 C. For a positive control for inhibition of protein synthesis, 
100 mg/ml of cycloheximide was added to DMSO treated cells and incubated at 37°C for 30 
minutes prior to addition of OPP. Cells were then washed with ice-cold phosphate-buffered 
saline (PBS) and fixed in 500 μL of PBS with 1% paraformaldehyde (PFA) for 15 minutes 
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on ice, then washed again in PBS. Cells were permeabilized with 500 μL of PBS + 3% FBS 
+ 0.1% saponin for 5 minutes then washed in PBS + 3% FBS. The Click-it Cell Reaction 
Buffer Kit (Thermo C10269) was used to conjugate 500 nM Alexa Flour647-Azide (Thermo 
A10277) to OPP following the manufacturer’s instructions. Samples were washed in PBS 
+ 3% FBS, then resuspended in 1 mL PBS. To control for background staining, a sample of 
DMSO treated cells was subjected to the same staining procedure, but no OPP was added. 
Relative Alexa647 fluorescence was quantified using a Becton Dickinson (BD) LSR II flow 
cytometer and analyzed using FlowJo software. At least 10,000 events were recorded per 
sample. Doublets were excluded prior to analysis. The time course was repeated in 
biological triplicate with error representing standard error of the mean. Flow Cytometry 
experiments were performed in the Vanderbilt University Flow Cytometry Shared Resource.
Cell Cycle Analysis—Cell cycle analyses were performed as described (Kim and 
Sederstrom, 2015), with slight modification. MV4:11 cells were treated for 0, 1, 2, 3 or 6 
days with 2 μM C6, 2 μM C6nc, or 0.1% DMSO vehicle control. Fresh media and 
compound was added on day three. At each time point, one million cells were collected per 
sample and washed once with PBS then resuspended in 500 μl of PBS. Cells were fixed by 
adding cells drop-wise to 4.5 mL ice cold 70% ethanol while vortexing, then incubated for at 
least two hours at 20°C. Cells were washed in FACS buffer (PBS with 2% FBS, 1 mM 
EDTA) then stained with 500 μl PI Staining Solution (PBS with 10 μg/mL propidium iodide, 
100 μg/mL RNase, 2 mM MgCl2) for 20 minutes at room temperature, protected from light. 
Propidium iodide fluorescence was measured using a BD LSR II Flow Cytometer and cell 
cycle distribution was analyzed using BD FACSDIVA software. At least 10,000 events were 
recorded per sample. Doublets were excluded prior to analysis of cell cycle distribution. The 
time course was repeated with three biological replicates and error bars represent the 
standard error of the mean. Flow Cytometry experiments were performed in the Vanderbilt 
University Flow Cytometry Shared Resource.
Induction of Apoptosis—MV4:11 cells were treated for 0, 1, 2, 3 or 6 days with 2 μM 
C6, 2 μM C6nc, or 0.1% DMSO only. Fresh media and compound was added on day 3. As a 
positive control for apoptosis induction, cells were treated with 2 μM Camptothecin for 4 
hours. 5×105 cells were collected per sample and resuspended in 100 μl of 1× Annexin V 
Binding Buffer (Invitrogen V13246). 0.5 μl of Alexa Flour488-conjugated Annexin V 
(Thermo A13201) was added per sample, then incubated for 15 minutes. Cells were 
resuspended in 400 μl fresh 1× Annexin V Binding Buffer + 10 ng of propidium iodide and 
incubated for 10 minutes. Samples were then kept on ice and Alexa Flour488 and propidium 
iodide fluorescence was measured using a BD LSR II Flow Cytometer and the percentage of 
apoptotic cells was analyzed using FlowJo software. At least 10,000 events were recorded 
per sample. After doublet exclusion, an unstained control sample was used to set the 
quadrant gating. The time course was repeated with three biological replicates and error bars 
represent the standard error of the mean. Flow Cytometry experiments were performed in 
the Vanderbilt University Flow Cytometry Shared Resource.
Immunofluorescence and Confocal Microscopy—General procedures for 
immunofluorescence were taken from (Nicolae et al., 2014). For nucleophosmin (NPM) 
Aho et al. Page 21
Cell Rep. Author manuscript; available in PMC 2019 April 04.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
staining, cells were treated for 72 hours with 4 μM C6, 4 μM C6nc or 0.1% DMSO only. For 
ɣ-H2AX staining, cells were treated for 24 hours with 4 μM C6, 4 μM C6nc or 0.1% DMSO 
only. As a positive control for DNA damage, cells were treated for 1 hour with 2 μM 
camptothecin. As a positive control for nucleolar stress, cells were treated with 5 nM 
actinomycin D for 6 hours (Burger et al., 2010). Cells were washed once in PBS, then 
100,000 cells/sample were attached to slides via a Cytospin for 3 minutes at 800 rpm. Cells 
were fixed with 4% paraformaldehyde for 10 minutes at room temperature, followed by 
extraction with 0.3% Triton X-100 for 10 minutes on ice. Slides were blocked with 5% BSA 
+ 0.1% Triton X-100 in PBS for 30 minutes at room temperature. Primary antibody was 
added (1:5,000 Abcam ab11174 for ɣ-H2AX, and 1:2,000 Sigma B0556 for NPM) in PBS 
with 3% BSA and incubated overnight at 4°C. After washing in PBS, secondary antibody [1 
drop Alexa Fluor488 goat anti-Rabbit ReadyProbes Reagent (Thermo R37116) in 3 mL PBS 
for ɣ-H2AX or 1:2,000 Alexa Fluor488 goat anti-mouse IgG (Thermo A11001) in 3% BSA 
in PBS for NPM] was added and incubated for 1 hour at room temperature. Slides were 
washed in PBS, then nuclei were counterstained with 20 μM DRAQ5 in PBS for 10 mins at 
37°C. Slides were mounted with ProLong Diamond Antifade mountant. Images were 
collected using a Leica TCS SP5 scanning confocal microscope. Nuclear ɣ-H2AX staining 
intensity was quantified for all cells in 5 representative fields of view imaged with the same 
laser power and gain settings with Fiji software (Schindelin et al., 2012) and plotted in Prism 
with error bars representing the standard deviation. The ratio of nuclear to nucleoplasmic 
NPM staining in individual cells from two biological replicates was quantified using Fiji and 
plotted in Prism with error bar representing the standard deviation. Prism was used to 
perform a oneway ANOVA with a post hoc Dunnett’s test in order to compare the mean of 
each treatment to that of the DMSO-only treated control sample for both the mean nuclear 
gamma-H2AX signal and ratio of nucleolar to nucleoplasmic NPM staining quantifications. 
Level of significance was determined using a 95% confidence interval.
Generation of Cell Lines Expressing Exogenous WDR5—pFlag-C2, which is a 
derivative of pcDNA3.1-Puro (+) encoding a FLAG tag for N-terminal fusions (Thomas et 
al., 2015), was used as the backbone to insert sequences encoding either (i) amino acids 1–
94 of Saccharomyces cerevisiae GAL4 fused to the HA epitope, or full-length human 
WDR5. Generation of the F133A mutant was accomplished using whole plasmid PCR with 
Q5 polymerase and primers WDR5–11 and WDR5–12 (Table S4). For production of stable 
transfectants, 40 μg of each plasmid was linearized by Pvu I digest and transfected into 
HEK293 cells using the calcium phosphate method. After two days Puromycin was added to 
the media at 1 μg/ml. Selection was complete, compared to cells transfected with 
pBluescript II SK(+), after approximately three weeks.
Lentiviral Production and Transductions—pLKO-p53-shRNA-941 and pLKO-p53-
shRNA-427 plasmids were a gift from Todd Waldman [Addgene plasmid # 25637 and # 
25636 respectively; (Kim et al., 2007). Scrambled shRNA pLKO.1 plasmid was a gift from 
David Sabatini [Addgene plasmid # 1864; (Sarbassov et al., 2005). pLKO.3G was a gift 
from Christophe Benoist & Diane Mathis (Addgene plasmid # 14748). To allow for GFP+ 
cell sorting instead of puromycin selection of transduced cells, shRNA sequences from 
pLKO-p53-shRNA-941, pLKO-p53-shRNA-427, and scrambled shRNA pLKO.1 were 
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cloned into the pLKO.3G vector using SpeI and NdeI restriction enzymes (NEB). to create 
plasmids pLKO.3G-p53-shRNA-941, pLKO.3G-p53-shRNA-427, and pLKO.3G-shRNA-
scrambled plasmids, respectively. These plasmids were transfected into HEK293T cells 
along with the pCMV-Pax2 and pMD2 packaging vectors using the calcium phosphate 
method. pCMV-Pax2 was a gift from Jonathan Epstein (Addgene plasmid # 36052) and 
pMD2.G was a gift from Didier Trono (Addgene plasmid # 12259). Virus-containing media 
was harvested 24 and 48 hours post-transfection and filtered through a 0.45 μm filter. For 
viral transduction, one million MV4:11 cells were resuspended in 2 mL RMPI-1640 + 10% 
FBS + 1% penicillin/streptomycin. 8 μg/ml polybrene and 1 mL of filtered virus was added 
to the cells and incubated for 20 minutes. Cells were centrifuged at 800 × g for 30 minutes 
then gently resuspended and plated in a 6-well plate. Cells were incubated overnight at 
37°C. The transduction procedure was repeated two more times. GFP+ cells were sorted 
using a BD FACSAria III with a 100 μm nozzle. Cell sorting was performed in the 
Vanderbilt University Flow Cytometry Shared Resource. shRNA mediated knock-down of 
p53 in sorted GFP+ cells was validated via western blot.
Generation of p53 null MV4:11 and Molm13 cell lines—Lentiviral production and 
transduction was completed as stated for shRNA knock-down experiments, above. 
plentiCRISPRv2, a gift from Feng Zhang (Addgene plasmid # 52961), was modified to 
express a gRNA against p53 (GAGCGCTGCTCAGATAGCGA; pLentiCRISPRv2–TP53) or 
EGFP (GAGCTGGACGGCGACGTAAA; pLentiCRISPRv2–EGFP). Two days after 
transduction, cells were selected with 2 mg/ml of puromycin for eight days. After selection 
with puromycin, the resistant cell populations were cloned by single cell sorting into a 96-
well plate using a BD FACSAria III. Clones were validated for p53 knockout by western 
blot and Tracking of Indels by Decomposition (TIDE) sequencing analysis (Brinkman et al., 
2014). Proliferation assays and p53 induction blots were done as for the p53 shRNA 
knockdown.
Chromatin Immunoprecipitation—Chromatin immunoprecipitation (ChIP) assays were 
performed as described (Thomas et al., 2015). Cells were treated with inhibitors, as 
indicated, then washed in PBS and cross-linked with 0.75%–1% formaldehyde at room 
temperature for 10 minutes. The reaction was quenched with 125 mM glycine for 10 
minutes at room temperature, after which cells were washed with ice cold PBS. Cells were 
lysed in Formaldehyde Lysis Buffer (50 mM HEPES pH 7.5, 140 mM NaCl, 1 mM EDTA, 
1% Triton, 1% SDS, and Complete Protease Inhibitor cocktail) using 250 μl of buffer per 
1×107 cells, on ice, for 10 minutes. Chromatin was sheared by 25-minute sonication 
(BioRuptor) to yield a mean chromatin size of ~250 bp, and debris cleared by centrifugation. 
Sheared chromatin was diluted 10-fold in Formaldehyde Lysis Buffer without SDS before 
immunoprecipitation overnight at 4°C using the appropriate antibody and Protein A agarose. 
Chromatin from 6 million cells was used per reaction. Immune complexes were washed 
sequentially with Low Salt Wash buffer (20 mM Tris pH 8.0, 150 mM NaCl, 2 mM EDTA, 
1% Triton), High Salt Wash Buffer (20 mM Tris pH 8.0, 500 mM NaCl, 2 mM EDTA, 1% 
Triton), LiCl Wash buffer (25 mM LiCl, 1 mM EDTA, 1% Triton) and twice with TE (pH 
8.0). Protein–DNA complexes were de-crosslinked overnight at 65°C in Elution Buffer (TE, 
0.1% SDS, 40 μg Proteinase K). Proteinase K was heat inactivated for 20 minutes 95°C then 
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150 μl of TE was added. 1 μl of DNA was used in a 15 μl PCR reaction using KAPA SYBR 
FAST qPCR Master Mix 2X Universal and quantified on an Eppendorf Realplex2 
Mastercycler in triplicate. ChIP signals were calculated as percent input. ChIP experiments 
were completed in biological triplicate with error bars representing the standard error of the 
mean.
Chromatin Immunoprecipitation–Sequencing—MV4:11 cells were grown to 106 
cells/ml and treated for 4 hours with 0.1% DMSO, 2 μM C6, or 2 μM C6nc. Cells were 
concentrated to 4 × 106 cells/ml in PBS and cross-linked with 1% formaldehyde for 10 
minutes at room temperature followed by quenching with 125 mM glycine for 10 minutes. 
Cells were washed with ice-cold PBS and lysed in 250 μl 1% SDS FA Buffer (50 mM 
HEPES, pH 7.5; 140 mM NaCl; 1 mM EDTA; 1% Triton X-100; 1% SDS; 1× Roche 
Protease Inhibitor, EDTA-Free) per 107 cells and incubated on ice for 10 minutes. 
Chromatin was sheared with a Bioruptor (Diagenode, UCD-200) on highest setting, 
alternating between 30 s on/30 s off, to achieve an average fragment size of ~250 
nucleotides; cellular debris was then cleared through centrifugation for 10 minutes at 16k g 
at 4°C. Sheared chromatin was diluted ten-fold with 0% SDS FA Buffer to achieve a final 
concentration of 0.1% SDS and IgG or appropriate anti-WDR5 antibody added. Samples 
were rotated overnight at 4°C. Protein-A agarose beads (Roche, 11 134 515 001) were 
washed three times with 1% FA Buffer and blocked for 20 minutes on rotator with 10 μg 
BSA and 100 μl 1% SDS FA Buffer per 15 μl bed volume of Protein-A agarose beads. 100 
μl blocked bead slurry was added to each sample and rotated for 4 hours at 4°C. Beads were 
washed by rotating beads for 5 minutes at room temperature with 1 mL of the following 
buffers: once with Low Salt Buffer, once with High Salt Buffer; once with LiCl Wash 
Buffer; and twice with TE. Washed chromatin-bound beads were suspended in 50 μl TE, 5 μl 
1% SDS, and 1 μl Proteinase K and incubated overnight at 65°C. The following day, 300 μl 
TE was added and protein removed by phenol chloroform extraction. DNA was precipitated 
by adding 36 μl 3 M NaOAc, pH 5.2, 10 μg glycogen, and 1 mL 100% ethanol and 
centrifugation for 10 minutes at 16k g at 4°C. DNA pellets were washed once with 70% 
ethanol and air-dried. DNA pellets were suspended in 100 μl TE and used for next 
generation sequencing (NGS) library preparation. Indexed libraries were made using the 
DNA Ultra II Library Prep Kit for Illumina (New England BioLabs, Inc., E7645). Library 
quality was assessed using the 2100 Bioanalyzer (Agilent) and libraries were quantitated 
using KAPA Library Quantification Kits (KAPA Biosystems). Pooled libraries were subject 
to 50 bp single-end sequencing according to the manufacturer’s protocol (Illumina HiSeq 
3000). Sequencing was performed by the Vanderbilt Technologies for Advanced Genomics 
(VANTAGE) Shared Resource. Bcl2fastq2 Conversion Software (Illumina) was used to 
generate de-multiplexed Fastq files.
Subcellular Fractionation—These assays were performed as described (Méndez and 
Stillman, 2000). MV4:11 cells were treated for 4 hours with 36 μM C3 or 0.1% DMSO only. 
1 ×107 cells were collected and washed twice in PBS. Cells were resuspended in 200 μl 
Buffer A [10 mM HEPES, pH 7.9, 10 mM KCl, 1.5 mM MgCl2, 0.34 M sucrose, 10% 
glycerol, 1 mM DTT (added fresh), 1× protease inhibitor cocktail (added fresh)] and 
incubated on ice for 8 minutes. Samples were centrifuged at 1,300 × g at 4°C for 5 minutes. 
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The supernatant (S1 fraction) and pellet (P1 fraction) were separated and S1 was clarified by 
high-speed centrifugation at 4°C for 10 minutes. The resulting supernatant (S2 fraction) was 
collected and the pellet (P2 fraction) was discarded. The P1 fraction was washed once with 
500 μl Buffer A and centrifuged 1 minute at 1,300 × g. The P1 fraction was lysed by 
resuspending in 100 μl Buffer B [3 mM EDTA, 0.2 mM EGTA, protease inhibitor cocktail 
(added just before use)] and incubating for 30 minutes on ice, followed by centrifugation at 
1,700 × g at 4C for 5 minutes. The resulting supernatant (S3 fraction) was separated from 
the chromatin-enriched pellet (P3 fraction). P3 was washed once with 500 μl Buffer B and 
resuspended in 100 μl SDS sample buffer and boiled for 10 minutes. 5% of each fraction 
was run on an 8% SDS-PAGE gel and protein distribution probed by western blotting.
Polysome fractionation—Polysome enrichment experiments were performed as 
previously described (Yang et al., 2006). Briefly, 15 × 106 MV4:11 cells were plated with 
either 5 μM C6 or DMSO control for 24 hours and then lysed in Polysomal Buffer (10 mM 
MOPS, pH 7.2, 250 mM NaCl 2.5 mM MgOAc, 0.5% NP-40, 200 ug/ml heparin; containing 
50 mg/ml cyclohexamide, 1 mM PMSF, 20 units of Superase Inhibitor, and protease 
inhibitor cocktail for 10 min on ice. Debris were cleared by centrifugation. A portion of the 
supernatant representing the total RNA was served as the total RNA for extraction. 
Polysomes in the supernatant were recovered by centrifugation (100,000 × g) for 1 hr in a 
TLA 120.1 rotor. Pelleted polysomes were resuspended in polysomal buffer and all 
supernatant remaining served as the monsomal fraction. RNA from total, polysomal, and 
monosomal fractions were extracted using Trizol-LS (Thermo Scientific) followed by 
purification and DNase treatment using Direct-zol RNA miniPrep (Zymol). All extracted 
RNA was subjected to reverse transcription using MuLV reverse transcriptase as described 
below. Differences in mRNA levels between fractions were quantified using an Eppendorf 
Realplex2 Mastercycler using the Ct method. For each fraction, mRNAs of interest were 
normalized to GAPDH and then the percent of the total RNA for monosomal or polysomal 
fractions was calculated. These final values representing the percent monosomal or 
polysomal mRNA were then made relative to DMSO treatment.
Cycloheximide (CHX) Chase—MV4:11 cells were treated for 24 hours with 2 μM C6, 2 
μM Nutlin-3 or DMSO only. After 24 hours, two million cells were collected for each 
treatment as the “time 0” sample. To the remainder of the sample, CHX was added to a final 
concentration of 50 μg/ml. At time points of 15, 30, 60, 120, and 180 minutes, two million 
cells for each treatment were collected, snap frozen in liquid nitrogen, and stored at −80°C 
until processing. Cell pellets were lysed in 200 μl of Kischkel buffer (50 mM Tris pH 8.0, 
150 mM NaCl, 5 mM EDTA, 1% Triton X-100, protease inhibitor cocktail, 1 mM PMSF), 
extracts sonicated and then cleared by centrifugation. Laemmli Sample buffer was added and 
samples were boiled for 10 mins before running on a 4%–20% mini-PROTEAN TGX gel 
(BioRad) and transferring to PVDF membrane. Membranes were blocked in 5% milk in 
TBST for 20 minutes then probed with appropriate antibodies.
RT-qPCR Quantification of mRNA Expression—Cells were lysed in 500 μl Trizol, 
after which total RNA was extracted using the Zymo Research Direct-zol RNA MiniPrep kit 
with on-column DNase digestion. After extraction, 1 μg of RNA was reverse transcribed 
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using MuLV reverse transcriptase (Life Tech N8080018) in 20 μl reaction, then diluted 
three-fold with nuclease-free water. 1 μl of cDNA was used in a 15 μl qPCR reaction using 
KAPA SYBR FAST qPCR Master Mix 2X Universal and quantified on an Eppendorf 
Realplex2 Mastercycler in triplicate. Relative mRNA expression of genes of interest was 
quantified using the CT method, normalized to signals from GAPDH. mRNA expression 
studies were completed in triplicate with error bars representing the standard error of the 
mean.
PRO-Seq—30 million MV4:11 cells were treated with compound C3 and harvested after 
either 15, 30, or 60 minutes. As a reference control, cells were treated with 0.1% DMSO for 
60 minutes. Cells were washed twice with cold PBS, resuspended in 10 mL of cold swelling 
buffer (10 mM Tris-Cl pH 7.5, 2 mM MgCl2, 3 mM CaCl2, 300 mM Sucrose, protease 
inhibitors), and incubated on ice for 5 minutes. After incubation, cells were pelleted by 
centrifugation, resuspended in 2 mL cell lysis buffer (swelling buffer + 10% glycerol + 0.1% 
Triton X-100) and incubated on ice for 5 minutes. Cells were then Dounce-homogenized 50 
times, after which 5 mL of lysis buffer was added and nuclei collected by centrifugation. 
The nuclei were washed once with 5 mL lysis buffer, followed by one wash with 1 mL 
freezing buffer (50 mM Tris-Cl pH 8.3, 40% glycerol, 5 mM MgCl2, 0.1 EDTA), 
resuspended in freezing buffer at density of 2 × 107 nuclei/100 μl, and stored at −80°C until 
nuclear run-on assays could be performed.
Nuclear run-on assays were performed as described (Kwak et al., 2013). Briefly, nuclei were 
thawed on ice and 2 × 107/100 μL nuclei added to an equal volume of pre-warmed 2× 
nuclear run-on reaction mix (10 mM Tris-Cl pH 8.0, 300 mM KCl, 1% Sarkosyl, 5 mM 
MgCl2, 1 mM DTT, 375 μM ATP, biotin-11-CTP, GTP and UTP, and 0.8 U/μl SuperaseIN). 
Run-on reactions were performed for three minutes at 30°C, and then terminated by addition 
of three volumes of TRIzol LS. RNA was extracted and precipitated in isopropanol, 
followed by a 75% ethanol wash. Extracted RNA was fragmented by base hydrolysis using 
0.2 M NaOH on ice for 10 minutes. After incubation, the reaction was neutralized by 
addition of one volume of 1 M Tris-Cl, pH 6.8. Thirty microliters of Dynabeads® MyOne 
Streptavidin T1 magnetic beads (Invitrogen) were then added to collect biotinylated RNA 
fragments, and incubated on a nutator for 20 minutes at room temperature according to the 
manufacturer’s instructions. After incubation, beads were sequentially washed with high salt 
(2M NaCl, 50 mM Tris-Cl pH 7.4, 0.5% Triton X-100), medium salt (300 mM NaCl, 10 
mM Tris-Cl pH 7.4, 0.1% Triton X-100), and low salt (5 mM Tris-Cl pH 7.4, 0.1% Triton 
X-100) wash buffers. RNA was eluted from the beads by two TRIzol extractions followed 
by isopropanol precipitation and a 75% ethanol wash.
3’ RNA adaptor ligation was carried out in a 10 μL reaction containing 10 pmol of 3’ RNA 
adaptor, 10 U T4 RNA ligase I (NEB), 10 nmol of ATP, and SuperaseIN, at 20°C for 6 
hours. Adaptor-ligated biotinylated RNA was purified by Streptavidin bead binding and 
RNA extraction as described above. The 5’ ends of RNA fragments were repaired by 
incubation with Tobacco Acid Pyrophosphatase (TAP, Epicenter), followed by 
Polynucleotide Kinase (PNK, NEB) treatment according to manufacturer’s instructions. 
RNA was extracted using TRIzol and precipitated with isopropanol followed by a 75% 
ethanol wash. 5’ RNA adaptor ligation was carried out in a 10 μL reaction containing 10 
Aho et al. Page 26
Cell Rep. Author manuscript; available in PMC 2019 April 04.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
pmol of 5’ RNA adaptor, 10 U T4 RNA ligase I, 10 nmol ATP, and SuperaseIN, at 20°C for 
6 hours. Adaptor-ligated biotinylated RNA fragments were purified by Streptavidin bead 
binding and TRIzol extraction as described above, and then reverse-transcribed using 25 
pmol RP1 primer (for TRU-seq sequencing). An aliquot of cDNA was serially diluted and 
used for standard PCR amplification to determine optimal PCR cycle number. The final 
library amplification was carried out by using 12.5 pmol RPI-index primers (for TRU-seq 
barcodes, Illumina) and Phusion polymerase (NEB). Libraries were run on PAGE gel and 
and library fragments between 140 and 300 bp was excised. The libraries were purified and 
submitted to the Vanderbilt Technologies for Advanced Genomics (VANTAGE) for 
sequencing on an Illumina HiSeq 2000.
RNA-Seq—Cells were treated for 72 hours with 2 μM C6, 2 μM C6nc or 0.1% DMSO 
only. Cells were washed in PBS then lysed in 500 μl Trizol. RNA was isolated using the 
Zymo Research Direct-zol RNA MiniPrep kit with on-column DNase digestion following 
the manufacturer’s instructions. Library preparation with rRNA depletion and paired-end 
150 base pair sequencing on an Illumina HiSeq was performed by GENEWIZ. Prior to 
sequencing, RNA integrity was assessed by 2100 Bioanalyser (Agilent) and concentration 
was assayed by Qubit. RNA-Seq for MV4:11 cells treated with C6nc, C6 and DMSO was 
completed with 5 biological replicates.
p53/p21 Induction Western Blots—Cells were treated for 24 hours with C6nc and C6 
(2 μM for MV4:11 and 3 μM for Molm13), or 2 μM Nutlin-3, or a 0.1% DMSO only vehicle 
control. Four million cells were washed in PBS then lysed for 10 minutes on ice in 200 μl 
Kischkel buffer (50 mM Tris pH 8.0, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 
protease inhibitor cocktail, 1 μM PMSF). Whole cell extracts were sonicated for 15 s then 
clarified by centrifugation. Laemmli Sample buffer was added and samples were boiled for 
10 minutes before running on a 4%–20% mini-PROTEAN TGX gel (BioRad) and 
transferring to PVDF membrane. Membranes were blocked in 5% milk in TBST for 20 
minutes then probed with appropriate antibodies.
Induction of PARP1 cleavage—MV4:11 cells were treated for 1, 2, 3 or 6 days with 2 
μM C6nc and C6, or 0.1% DMSO only. Four million cells were washed in PBS then lysed 
for 10 minutes on ice in 200 μl Kischkel buffer (50 mM Tris pH 8.0, 150 mM NaCl, 5 mM 
EDTA, 1% Triton X-100, Protease inhibitor cocktail, 1 μM PMSF). Whole cell extracts were 
sonicated for 15 s then clarified by centrifugation. Laemmli Sample buffer was added and 
samples were boiled for 10 minutes before running on a 4%–20% mini-PROTEAN TGX gel 
(BioRad) and transferring to PVDF membrane. Membranes were blocked in 5% milk in 
TBST for 20 minutes then probed with appropriate antibodies.
QUANTIFICATION AND STATISTICAL ANALYSIS
ChIP-Seq Data Analysis—ChIP-Seq reads were aligned to the human genome using 
Bowtie2 (Langmead et al., 2009). Peaks in each sample were called using MACS2 with q-
value of 0.01 (Feng et al., 2012). Peaks were annotated using the Homer command 
annotatePeaks (http://homer.ucsd.edu/homer/). Consensus peaks in each condition were 
identified using DiffBind (Stark and Brown, 2011); peaks occurring at least two replicates in 
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each condition were included. Peaks identified in at least one condition were combined into 
a final peak set to identify differential peaks across conditions. Read counts were normalized 
to the total mapped reads, and differential peaks were determined by DESeq2 (Love et al., 
2014), which calculated the log2 fold changes, Wald test p values, and adjusted p values 
(False Discovery Rate, FDR) by the Benjamini-Hochberg procedure. Significantly changed 
peaks were assessed with FDR < 0.05.
RNA-Seq Data Analysis—RNA-Seq reads were aligned to the human reference genome 
hg19 using STAR (Dobin et al., 2013) and quantified by featureCounts (Liao et al., 2014). 
Read counts were normalized by the Relative Log Expression (RLE) method. Differential 
analysis were performed by DESeq2 (Love et al., 2014), which determined the log2 fold 
changes, Wald test p values, and adjusted p value (FDR) by the Benjamini-Hochberg 
procedure. The significantly changed genes were assessed with a FDR < 0.05.
PRO-Seq Analyses—Low quality reads were trimmed from raw reads using 
Trimmomatic-0.32 (Bolger et al., 2014). Reverse complements were generated using 
“fastx_reverse_complement” from FASTX-Toolkit. Reverse-complemented reads were 
aligned to the human genome hg19 using Bowtie2 [version 2.2.4; (Langmead and Salzberg, 
2012). Reads mapped to rRNA loci and reads with mapping quality of less than 10 were 
removed. The reads were normalized by the RLE implemented in the DESeq2 (Love et al., 
2014). NRSA (http://bioinfo.vanderbilt.edu/NRSA/), a tool to provide a comprehensive 
analysis on nascent transcriptional profiles for known genes and novel enhancers, was used 
to estimate RNA polymerase abundance in proximal-promoter and gene body regions of 
genes, to calculate pausing index and pausing index alterations, and to detect enhancers and 
quantify eRNA changes. Briefly, the promoter-proximal region is defined by examining each 
50 bp window with a 5 bp sliding step along the coding strand spanning ± 500 bp from 
known TSSs. The 50 bp region with the largest number of reads is considered as the 
promoter-proximal region and its read density is calculated (Core et al., 2008). The gene 
body is defined as the region from +1 kb downstream of a TSS to its transcription 
termination site (TTS). Pausing index for each gene is calculated as the ratio of promoter-
proximal density over gene body density. Significance of pausing is evaluated by Fisher’s 
exact test (Core et al., 2008). NRSA first calls novel transcripts using HOMER, and then 
identifies intergenic, bidirectional transcripts as eRNA pairs (Hah et al., 2011, 2013). NRSA 
detects enhancers by integrating those eRNA pairs. Enhancers are considered to be novel if 
their centers do not fall in any enhancer region based on the FANTOM5 database (Lizio et 
al., 2015). DESeq2 (Love et al., 2014) was implemented to detect significant transcriptional 
changes for promoter-proximal, gene body regions, and enhancers, accounting for the batch 
effect. Transcriptional changes were assessed with a FDR < 0.05 and a fold change ≥ 1.5 
were considered significant.
DATA AND SOFTWARE AVAILABILITY
All genomic datasets (for ChIP-Seq, RNA-Seq, and PRO-Seq) have been deposited at the 
Gene Expression Omnibus (GEO) with accession number GEO: GSE115377. X-ray crystal 
structures have been deposited at the Protein Data Bank (PDB) with accession codes PDB: 
6DY7, 6EY1, 6E22, 6E1Z, 6DYA, and 6E23.
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Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• WDR5 is a regulator of ribosome protein gene transcription
• The WIN site of WDR5 tethers it to chromatin
• Potent small molecule inhibitors of the WIN site displace WDR5 from 
chromatin
• WIN site inhibitors induce nucleolar stress and p53-dependent apoptosis
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Figure 1. Discovery of Small Molecule WIN Site Inhibitors
(A) Elaboration of fragment hit C1 into our first-generation chemical probe C3.
(B–D) X-ray co-crystal structures of WDR5 bound to (B) the fragment hit C1 (PDB: 6DY7), 
(C) C2 (PDB: 6E1Y), and (D) C3 (PDB: 6E22).
(E) Elaboration of fragment hit C4 into our second-generation chemical probe C6.
(F–H) X-ray co-crystal structures of WDR5 bound to (F) the fragment hit C4 (PDB: 6E1Z), 
(G) C5 (PDB: 6DYA), and (H) C6 (PDB: 6E23).
See also Figure S1 and Tables S1 and S2.
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Figure 2. WIN Site Inhibition Induces Apoptosis and Kills Cells in a p53-Dependent Manner
(A) MV4:11 cells were treated with DMSO, 2 μM C6, or C6nc; samples collected at the 
indicated time points; and live cells quantified via trypan blue exclusion. To prevent culture 
overgrowth, the DMSO- and C6nc-treated samples were replated at day 3 (“replate”) to the 
original starting density and treatment continued.
(B) Stacked bar graph showing the distribution of cell-cycle phases, determined by flow 
cytometry, in MV4:11 cells treated with DMSO, 2 μM C6nc, or C6 for the indicated times.
(C) Western blot for cleaved PARP-1 (P-cl), or histone H3, in lysates from MV4:11 cells 
treated with DMSO, 2 μM C6nc, or C6 for the indicated times.
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(D) Bar graph showing the percentage of annexin V+ and propidium iodide-negative (PI−) 
cells in MV4:11 cells treated with DMSO, 2 μM C6nc, or C6 for the indicated days. 
Camptothecin (CPT) is a positive control for the induction of apoptosis.
(E) Western blot, showing the effects of DMSO, 2 μM C6, or C6nc (24 h), on p53 and p21 
protein levels in MV4:11 cells. Histone H3 is a loading control.
(F) Western blot, showing p53 levels in MV4:11 cells treated with 2 μM C6nc or C6 for 24 
h, and expressing either (1) a scrambled shRNA control (scr), (2) shRNA 427 against p53 
(sh_427), or (3) shRNA 941 against p53 (sh_941).
(G) Dose-response curves for compound C6 and its negative control, C6nc, in MV4:11 cells 
expressing the indicated shRNAs. GI50 results from 3-day treatment with C6 are shown to 
the right of the appropriate curves.
(H) Western blot, showing the effects of DMSO, 3 μM C6, or C6nc (24 h), on p53 and p21 
protein levels in Molm13 cells.
(I) Western blot, showing p53 levels in the clones of Molm13 cells that were CRISPR 
targeted with either an EGFP (clones 2e and 3e) or a p53 (clones 2p and 4p) guide RNA 
(gRNA). Cells were treated with C6 or C6nc at 3 μM for 24 h before analysis.
(J) Dose-response curves for compound C6 (3-day treatment) in the modified Molm13 cells 
described in (I). The GI50 values are 7 μM for clones 2e and 3e, 18 μM for clone 2p, and 15 
μM for clone 4p.
(A, D, G, and J) Error bars represent SEM.
See also Figure S3.
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Figure 3. WIN Site Blockade Inhibits WDR5-Bound Genes Linked to Protein Synthesis
(A) Table shows the number of transcripts significantly (FDR < 0.05) altered by 3 days of 
treatment of MV4:11 cells with 2 μM C6 or C6nc, compared to DMSO control.
(B) Gene Ontology (GO) enrichment clusters for genes significantly repressed by C6 
treatment of MV4:11 cells, as determined by RNA-seq. Numbers in italics represent the 
number of repressed genes in each category.
(C) Highly significantly enriched (FDR q = 0.0) Reactome gene sets (defined in the 
Molecular Signatures Database), determined by gene set enrichment analysis (GSEA) of 
RNA-seq from MV4:11 cells treated with 2 μM C6.
(D) Overlap of genomic binding sites for WDR5 in MV4:11 cells, as determined by ChIP-
seq with either the D9E1I or 429A anti-WDR5 antibodies.
(E) Top eight GO enrichment categories for genes bound by WDR5 in DMSO-treated 
MV4:11 cells.
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(F) Distribution of WDR5 binding sites in MV4:11 cells, binned according to the distance 
from the annotated TSS. Output includes either all of the WDR5 binding events (Set-wide) 
or only those at RPGs (Ribosome). RGA, region-gene association.
(G) Venn diagram, showing overlap of genes bound by WDR5 (ChIP-seq), with genes 
induced by C6 treatment (RNA-seq) in MV4:11 cells.
(H) As in (G), except overlap is between the genes bound by WDR5 and those repressed by 
C6 treatment.
See also Figure S4.
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Figure 4. WIN Site Blockade Induces Translational Stress and Stimulates p53 Synthesis
(A) Representative flow cytometry histograms showing Alexa Fluor 647-labeled OPP 
incorporation into nascent polypeptides of MV4:11 cells treated with DMSO, 2 μM C6nc, or 
C6. As a control for the inhibition of translation, CHX was added to cells 30 min before the 
addition of OPP.
(B) Quantification of the nucleolus:nuclear ratio of NPM1 in MV4:11 cells treated with 4 
μM C6 (or C6nc) for 3 days. ns, no significant difference (p = 0.1). ****p < 0.0001. Data are 
shown as a box and whisker plot. Box extends from the 25th to 75th percentile with median 
marked by the middle line, whiskers extend from minimum to maximum point.
(C) MV4:11 cells were treated with DMSO, 2 μM C6, or 2 μM nutlin-3 for 24 h, after which 
CHX was added and proteins sampled at the indicated time points (CHX; in min). p53 and 
histone H3 (loading control, shown here for the C6 treatment) were detected by Western 
blotting.
(D) RT-qPCR analysis of the indicated mRNA levels on polysomal or monosomal fractions 
collected following the treatment of MV4:11 cells with 5 μM C6 or DMSO for 24 h. Data 
are shown as a box and whisker plot of relative mRNA changes of indicated genes in each 
fraction, relative to DMSO. Box extends from the 25th to the 75th percentile, with the 
median marked by the middle line; whiskers extend from minimum to maximum point; n = 
3 experiments.
See also Figure S5.
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Figure 5. WIN Site Inhibitors Act Rapidly to Displace WDR5 from Chromatin and Inhibit 
Transcription at WDR5-Bound Genes
(A) Heatmap listing genes with significant changes in gene body-associated polymerases in 
MV4:11 cells treated with 36 μM compound C3, as determined by PRO-seq. The orange bar 
indicates whether WDR5 is bound to the locus. RPS17 (*) and RPL17(***) are listed twice, 
because two distinct National Center for Biotechnology Information Reference Sequence 
Database (RefSeq) IDs were called for those loci. LOC100506548 (**) is the read-through 
transcription from RPL37.
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(B) Heatmaps displaying log2-transformed fold change of PRO-seq read counts in 200 bp 
bins ± 5 kb around the TSS of loci showing gene body changes after C3 treatment.
(C) ChIP-PCR analysis of WDR5 binding at 5 loci in MV4:11 cells treated with DMSO 
(DM), or 36 μM of C3 (or C3nc) for 4 h. Chromatin samples were immunoprecipitated with 
an anti-WDR5 antibody (D9E1l) or an immunoglobulin G (IgG) control. Data are presented 
as a percentage of the signal for the same amplicon in the input chromatin.
(D) Western blot, showing WDR5 distribution in the soluble (S2), soluble nuclear (S3), or 
insoluble chromatin (P3) fractions of MV4:11 cells treated for 4 h with DMSO or 36 μM of 
C3. Histone H3 is a control for the specificity of the insoluble chromatin fraction.
(E) ChIP-PCR analysis of FLAG (FL)-tagged WDR5, wild-type (WT), or a WIN site mutant 
(F133A), stably expressed in HEK293 cells. Vector cells are the negative control; ChIP was 
performed with an anti-FLAG antibody.
(F) Scatterplot of normalized average read counts for WDR5 binding peaks in DMSO-, 
C6nc-, and C6-treated MV4:11 cells. Peaks are ranked based on read counts in DMSO-
treated cells.
(C and E) Error bars represent SEM.
See also Figure S6.
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